```
=> s l6 and (147511-69-1/rn)
           552 147511-69-1
            17 147511-69-1D
           545 147511-69-1/RN
                 (147511-69-1 (NOTL) 147511-69-1D )
L9          78 L6 AND (147511-69-1/RN)

=> focus
PROCESSING COMPLETED FOR L9
L10         78 FOCUS L9 1-

=> d ibib abs hitstr 1-78

L10  ANSWER 1 OF 78  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2002:222780  CAPLUS
DOCUMENT NUMBER:         137:226042
TITLE:                   Pitavastatin: Itavastatin, nivastatin,
                         NK 104, NKs 104,
                         P 872441
AUTHOR(S):               Anon.
CORPORATE SOURCE:        N. Z.
SOURCE:                  Drugs in R&D (2002), 3(1), 58-60
                         CODEN: DRDDFD; ISSN: 1174-5886
PUBLISHER:               Adis International Ltd.
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
AB   A review discusses the pharmacokinetics, adverse events, pharmacodynamics,
     and therapeutic trials of pitavastatin.  Pitavastatin
     inhibits HMG-CoA reductase, a rate-limiting key enzyme of cholesterol
     synthesis pathway.
IT   147511-69-1, Pitavastatin
     RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
     activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
     study); USES (Uses)
        (pharmacokinetics, adverse effects, pharmacodynamics, and therapeutic
        trials of pitavastatin)
RN   147511-69-1  CAPLUS
CN   6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-
     dihydroxy-, (3R,5S,6E)-  (CA INDEX NAME)

Absolute stereochemistry.  Rotation (+).
Double bond geometry as shown.
```




```
REFERENCE COUNT:         10    THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 2 OF 78  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2002:903370  CAPLUS
DOCUMENT NUMBER:         138:378498
```

TITLE: Metabolic fate of pitavastatin (NK -104), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: effects on drug-metabolizing systems in rats and humans

AUTHOR(S): Fujino, Hideki; Yamada, Iwao; Shimada, Syunsuke; Nagao, Takeshi; Yoneda, Michiaki

CORPORATE SOURCE: Tokyo Research Laboratories, Kowa Company Ltd., Tokyo, Japan

SOURCE: Arzneimittel-Forschung (2002), 52(10), 745-753
CODEN: ARZNAD; ISSN: 0004-4172

PUBLISHER: Editio Cantor Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Pitavastatin (CAS 147526-32-7, NK-104) is a new and very potent competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase and was approved for treatment of hyperlipoproteinemia. Pitavastatin was studied for its effects on hepatic microsomal drug metabolism in rats, and the activities of several drug-metabolizing enzymes were measured. No induction of the drug metabolizing enzymes (aniline hydroxylase, aminopyrine N-demethylase, 7-ethoxycoumarin O-deethylase, and UDP-glucuronic acid transferase) was found in the pitavastatin group compared to the control after the multiple administrations of pitavastatin at the dosage of 1-10 mg/kg per day for 7 days. Based on several different in vitro approaches, it is concluded that CYP2C9 is the enzyme responsible for the metabolism of pitavastatin and no metabolite is present in renal and intestinal microsomes. The CYP2C9 polymorphism was not involved in the pitavastatin metabolism No inhibitory effect in CYP-mediated metabolism was detected on the tolbutamide 4-hydroxylation (CYP2C9) and testosterone 6β-hydroxylation (CYP3A4) in the presence of pitavastatin. The results suggested that pitavastatin did not affect the drug-metabolizing systems.

IT 147511-69-1, Pitavastatin 147526-32-7, NK-104
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin (NK-104) on drug-metabolizing systems in rats and humans)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 147526-32-7 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-

dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:306319 CAPLUS
DOCUMENT NUMBER: 137:288438
TITLE: Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs
AUTHOR(S): Kojima, Junji; Ohshima, Takeshi; Yoneda, Michiaki; Sawada, Hironobu
CORPORATE SOURCE: Tokyo Research Laboratories, Pharmaceutical Division, Kowa Co., Ltd., Tokyo, 189-0022, Japan
SOURCE: Yakubutsu Dotai (2001), 16(6), 497-502
CODEN: YADOEL; ISSN: 0916-1139
PUBLISHER: Nippon Yakubutsu Dotai Gakkai
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The disposition of pitavastatin and pitavastatin lactone, which are mutually converted in the circulatory system, was investigated after i.v. administration of pitavastatin in dogs equipped with chronic bile-duct catheters. The plasma concentration of pitavastatin declined three-exponentially after dosing in the dogs with both diverted and non-diverted bile-flow. The terminal elimination half-life (T1/2) of pitavastatin in the diverted and non-diverted conditions was 3.12 and 5.01 h, and that of pitavastatin lactone 4.50 and 7.23 h, resp. The diverted bile-flow decreased the AUC0-24hr for pitavastatin and its lactone to 66 and 64%, resp. In the dogs with the diverted bile-flow, 56.1% and 4.2% of the dose was recovered in the bile as pitavastatin and its lactone, resp. The biliary clearance (CLb) of pitavastatin and its lactone was 32.5 and 6.8 mL/min, resp., and the CLb of pitavastatin was about 4.8-fold that of its lactone. In the dogs whose bile-flow was not diverted, the cumulative biliary excretion of pitavastatin and its lactone was estimated from the AUC0-24hr and CLb of both forms of pitavastatin. The estimated amount was increased by 46% compared with that in the dogs with the diverted bile-flow. This indicates that the increase reflects the actual contribution of the enterohepatic circulation.

IT 141750-63-2 147511-69-1, Pitavastatin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological

study); USES (Uses)
(effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs)

RN 141750-63-2 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:417415 CAPLUS

DOCUMENT NUMBER: 138:83169

TITLE: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

AUTHOR(S): Noji, Yoshihiro; Higashikata, Toshinori; Inazu, Akihiro; Nohara, Atsushi; Ueda, Kosei; Miyamoto, Susumu; Kajinami, Kouji; Takegoshi, Tadayoshi; Koizumi, Junji; Mabuchi, Hiroshi

CORPORATE SOURCE: Graduate School of Medical Science, Division of Cardiovascular Medicine, Vascular Medicine, Molecular Genetics of Cardiovascular Disorders (The Second

Department of Internal Medicine), Kanazawa University, Kanazawa, 920-8641, Japan
SOURCE: Atherosclerosis (Shannon, Ireland) (2002), 163(1), 157-164
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The clin. efficacy and safety of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor, during long-term treatment, were examined in 25 patients (male/female=11/14, mean age=53±13 (mean±SD) years) with heterozygous familial hypercholesterolemia (FH). After a period on placebo of >4 wk, 2 mg/day of pitavastatin was administered for 8 wk, and the dose was increased to 4 mg/day for up to 104 wk. Total cholesterol (TC) decreased by 31% from the initial value of 340±57 to 237±40 mg/dL (P<0.0001) at week 8. During treatment with the higher dose, TC decreased even further to 212±35 mg/dL at week 12; it decreased by 37% from the initial value (P<0.0001). Similarly, the baseline low-d. lipoprotein (LDL)-cholesterol (LDL-C) decreased by 41% at week 8, and by 49% at week 12, from 267±61 mg/dL at baseline. These findings indicate a dose-dependent effect of the drug on TC and LDL-C concns. To examine whether the levels of circulating matrix metalloproteinases (MMPs) and their endogenous inhibitors (tissue inhibitors of metalloproteinases: TIMPs) are altered during lipid-lowering therapy, we also measured their plasma levels. The mean levels of MMP-2 and MMP-3 were significantly increased. No significant alteration was found in MMP-9, TIMP-1 and TIMP-2 levels. As for the safety of pitavastatin, adverse reactions were observed in one case (4%) of subjective and objective symptoms. The effects of pitavastatin on TC and LDL-C were stable during long treatment of patients with heterozygous FH.

IT 147511-69-1, Pitavastatin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment with pitavastatin of patients with heterozygous familial hypercholesterolemia)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:393050 CAPLUS
DOCUMENT NUMBER: 137:163683
TITLE: Clinical efficacy of pitavastatin, a new

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-blind, three-group parallel comparison

AUTHOR(S): Saito, Yasushi; Yamada, Nobuhiro; Teramoto, Tamio; Itakura, Hiroshige; Hata, Yoshiya; Nakaya, Noriaki; Mabuchi, Hiroshi; Tushima, Motoo; Sasaki, Jun; Goto, Yuichiro; Ogawa, Nobuya

CORPORATE SOURCE: The Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan

SOURCE: Arzneimittel-Forschung (2002), 52(4), 251-255
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Pitavastatin (CAS 147526-32-7, NK-104), the first totally synthetic 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor discovered in Japan, was examined Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-d. lipoprotein cholesterol (LDL-C) at doses of 1 mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/day to 4 mg/day. It also significantly decreased the serum levels of triglycerides (TG) within this dose range. There was no dose-dependence of the incidence of adverse reactions to pitavastatin.

IT 147511-69-1, Pitavastatin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin (3-hydroxy-3-methylglutaryl CoA reductase inhibitor) effect in hyperlipidemia patients)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:22445 CAPLUS

DOCUMENT NUMBER: 139:159390

TITLE: Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

AUTHOR(S): Fujino, H.; Yamada, I.; Shimada, S.; Yoneda, M.;

Kojima, J.
CORPORATE SOURCE: Tokyo New Drug Research Laboratories I, Kowa Company Ltd, 2-17-43 Noguchicho, Higashimurayama, Tokyo, 189-0022, Japan
SOURCE: Xenobiotica (2002), Volume Date 2003, 33(1), 27-41
CODEN: XENOBH; ISSN: 0049-8254
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase little metabolized in hepatic microsomes. Pitavastatin lactone, which can be converted back to the unchanged form, is the major metabolite of pitavastatin in humans. To clarify the mechanism of the lactonization of pitavastatin and the metabolic properties of the lactone, we performed expts. in vitro. On addition of UDP-glucuronic acid, human hepatic microsomes produced pitavastatin lactone and an unknown metabolite (UM-2). UM-2 was converted to its unchanged form by enzymic hydrolysis and to a lactone form non-enzymically. Using several human UGT-expressing microsomes, UGT1A3 and UGT2B7 were principally responsible for glucuronidation of pitavastatin leading to lactonization. No marked difference in intrinsic clearance between pitavastatin and its lactone form was detected in human hepatic microsomes. Pitavastatin lactone showed no inhibitory effects on CYP2C9- and CYP3A4-mediated metabolism of model substrates in contrast to other HMG-CoA reductase inhibitors. The mechanism of pitavastatin lactone formation has been clarified, in that glucuronidation by UGT occurs first followed by lactonization via an elimination reaction. It was also found that pitavastatin lactone demonstrates no drug-drug interactions.
IT 141750-63-2, Pitavastatin lactone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism of pitavastatin, an inhibitor of HMG-CoA reductase and role of human UDP-glucuronosyltransferase enzymes involved in lactonization)
RN 141750-63-2 CAPLUS
CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 147511-69-1, Pitavastatin
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(metabolism of pitavastatin, an inhibitor of HMG-CoA reductase and role of human UDP-glucuronosyltransferase enzymes involved in lactonization)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-

dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:790222 CAPLUS
DOCUMENT NUMBER: 137:299919
TITLE: Stable pharmaceutical composition containing NK-104
INVENTOR(S): Muramatsu, Toyojiro; Mashita, Katsumi; Shinoda, Yasuo; Sassa, Hironori; Kawashima, Hiroyuki; Tanizawa, Yoshio; Takeuchi, Hideatsu
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 894,279, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6465477	B1	20021015	US 1999-436789		19991108 <--
PRIORITY APPLN. INFO.:			JP 1995-354654	A	19951222
			US 1997-894279	B2	19970818

AB A pharmaceutical composition comprises (E)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropylquinolin-3'-yl]-6-heptenoic acid (NK-104) or its salt or ester, of which the aqueous solution or dispersion has a pH of 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. Tablets contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropyl Me cellulose-2910 2.0, Mg aluminometasilicate 2.4, and Mg stearate 1.2 mg/tablet.
IT 147511-69-1, NK 104
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical composition containing NK-104)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:112489 CAPLUS
DOCUMENT NUMBER: 139:46353
TITLE: Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase-effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice
AUTHOR(S): Fujino, Hideki; Yamada, Iwao; Shimada, Syunsuke; Kojima, Junji
CORPORATE SOURCE: Tokyo New Drug Research Laboratories I, Kowa Company Ltd., Tokyo, 189-0022, Japan
SOURCE: Drug Metabolism and Pharmacokinetics (2002), 17(5), 449-456
CODEN: DMPRB8; ISSN: 1347-4367
PUBLISHER: Japanese Society for the Study of Xenobiotics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase. In the current study, to elucidate the hepatobiliary excretion of pitavastatin, we investigated the plasma concentration and biliary excretion of 14C-pitavastatin in EHBR. We also evaluated the distribution of pitavastatin in mdr1a/b knockout mice by whole body autoradiog. and quant. radioassay. In view of the widespread clin. use of pitavastatin and the importance of drug-drug interaction, the inhibitory effect on Pgp-mediated activation of ATPase was also investigated. No marked difference was observed in the plasma concentration and biliary excretion of radioactivity between SDR and EHBR after dosing of 14C-pitavastatin. Little radioactive transfer into the brain was detected in mdr1a/b knockout mice and the ATPase activity of human Pgp was negligible in the presence of pitavastatin. Moreover, no inhibitory effect on the Pgp-mediated activation of ATPase by verapamil was found in the presence of pitavastatin over a wide concentration range. These results indicated that a cMOAT and Pgp-mediated transport mechanism did not play a major role in the distribution of pitavastatin.
IT 147511-69-1, Pitavastatin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biliary excretion of pitavastatin across the canalicular membrane in relation to cMOAT and P-glycoprotein)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-

dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:340851 CAPLUS
DOCUMENT NUMBER: 137:320163
TITLE: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
AUTHOR(S): Saito, Yasushi; Yamada, Nobuhiro; Teramoto, Tamio; Itakura, Hiroshige; Hata, Yoshiya; Nakaya, Noriaki; Mabuchi, Hiroshi; Tushima, Motoo; Sasaki, Jun; Ogawa, Nobuya; Goto, Yuichiro
CORPORATE SOURCE: School of Medicine, The Second Department of Internal Medicine, Chiba University, Chiba, Japan
SOURCE: Atherosclerosis (Shannon, Ireland) (2002), 162(2), 373-379
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pitavastatin (p-INN) is a novel and fully synthetic 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, with a cholesterol-lowering action stronger than that of other statins currently in use. A 12-wk, multi-center, randomized, double-blind, controlled study was conducted to confirm the efficacy and safety of pitavastatin compared with pravastatin, an agent for using to reduce low d. lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients. Patients were recruited at 43 institutes in Japan. Following more than 4 wk run-in period, 240 patients were randomized to receive 2 mg of pitavastatin or 10 mg of pravastatin daily. At 12 wk post-randomization, the pitavastatin group showed significantly lower LDL-C levels by -37.6% from baseline compared with -18.4% in the pravastatin group ($P<0.05$). Pitavastatin also significantly lowered total cholesterol (TC) by -28.2% compared with -14.0% of pravastatin ($P<0.05$). The LDL-C target level of <140 mg/dL was attained in 75% of the patients treated with pitavastatin, compared with 36% of those in the pravastatin group ($P<0.05$). Pitavastatin also significantly reduced triglycerides (TG), apo B, C-II and C-III, compared with pravastatin, and increased HDL-C, apo A-I and A-II, to the same extent of pravastatin. Safety was assessed by monitoring adverse events and measuring clin. laboratory parameters. The adverse event profile was similar for both treatment groups and neither treatment caused clin.

relevant laboratory abnormalities. These results indicated that pitavastatin was more effective than pravastatin, and both drugs were well-tolerated in the treatment of hypercholesterolemia.

IT 147511-69-1, Pitavastatin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparing the efficacy and safety of pitavastatin vs. pravastatin in patients with primary hypercholesterolemia)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:149001 CAPLUS
DOCUMENT NUMBER: 139:239363
TITLE: Pitavastatin (Nissan/Kowa Yakuhin/Novartis/Sankyo)
AUTHOR(S): Flores, Nicholas A.
CORPORATE SOURCE: Institute of Urology and Nephrology, Division of Applied Physiology, University College London, London, W1W 7EY, UK
SOURCE: Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2002), 3(9), 1334-1341
CODEN: COIDAZ; ISSN: 1472-4472
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Pitavastatin (nisvastatin) is an HMG CoA reductase inhibitor being developed jointly by Nissan, Kowa Kogyo, Novartis and Sankyo for the potential treatment of atherosclerosis and hyperlipidemia.

IT 147511-69-1P, Pitavastatin
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarteriosclerotic, antihypercholesterolemic, and antihyperlipidemic actions of pitavastatin)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:669870 CAPLUS
DOCUMENT NUMBER: 136:79688
TITLE: Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts
AUTHOR(S): Ohnaka, Keizo; Shimoda, Seiko; Nawata, Hajime; Shimokawa, Hiroaki; Kaibuchi, Kozo; Iwamoto, Yukihide; Takayanagi, Ryoichi
CORPORATE SOURCE: Department of Geriatric Medicine, Kyushu University, Higashi-ku, Fukuoka, 812-8582, Japan
SOURCE: Biochemical and Biophysical Research Communications (2001), 287(2), 337-342
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To clarify the mechanism of the stimulatory effect of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors (statins) on bone formation, we investigated the effect of pitavastatin, a newly developed statin, on expression of bone morphogenetic protein-2 (BMP-2) and osteocalcin in primary cultured human osteoblasts. Pitavastatin increased the expression level of mRNA for BMP-2, and much more effectively for osteocalcin. This stimulatory effect was abolished by the addition of geranylgeranyl pyrophosphate, an essential mol. for prenylation of small GTP-binding proteins such as Rho GTPase, but not by inhibitors of nitric oxide synthase and various protein kinases. Pitavastatin suppressed the Rho-associated kinase (Rho-kinase) activity. Hydroxyfasudil, a specific inhibitor of Rho-kinase, increased BMP-2 and osteocalcin expression. These mRNA levels were strongly suppressed by dexamethasone, but restored by co-treatment with hydroxyfasudil. These observations suggest that the Rho-kinase neg. regulates bone formation and the inhibition of Rho and Rho-kinase pathway is the major mechanism of the statin effect on bone. Moreover, a Rho-kinase inhibitor may be a new therapeutic reagent for the treatment of osteoporosis such as glucocorticoid-induced osteoporosis. (c) 2001 Academic Press.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:503284 CAPLUS
DOCUMENT NUMBER: 127:113387
TITLE: Pharmaceutical composition containing quinolinheptenoic acid derivatives stabilized with a basic agent
INVENTOR(S): Muramatsu, Toyojiro; Mashita, Katsumi; Shinoda, Yasuo; Sassa, Hironori; Kawashima, Hiroyuki; Tanizawa, Yoshio; Takeuchi, Hideatsu
PATENT ASSIGNEE(S): Kowa Company, Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723200	A1	19970703	WO 1996-JP3722	19961220 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2213608	A1	19970703	CA 1996-2213608	19961220 <--
CA 2213608	C	20030708		
ZA 9610792	A	19970709	ZA 1996-10792	19961220 <--
AU 9711715	A	19970717	AU 1997-11715	19961220 <--
AU 725622	B2	20001019		
EP 814782	A1	19980107	EP 1996-942588	19961220 <--
EP 814782	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
CN 1189098	A	19980729	CN 1996-192065	19961220 <--
JP 11503763	T	19990330	JP 1997-523500	19961220 <--
JP 3276962	B2	20020422		
RU 2142790	C1	19991220	RU 1997-114095	19961220 <--
HU 9903536	A2	20000328	HU 1999-3536	19961220 <--
HU 9903536	A3	20010628		
CZ 288545	B6	20010711	CZ 1997-2681	19961220 <--

IL 121565	A	20020210	IL 1996-121565		19961220 <--
AT 228354	T	20021215	AT 1996-942588		19961220 <--
SK 282991	B6	20030109	SK 1997-1160		19961220
ES 2183023	T3	20030316	ES 1996-942588		19961220
PT 814782	T	20030430	PT 1996-942588		19961220
PL 186907	B1	20040331	PL 1996-321868		19961220
TW 436294	B	20010528	TW 1996-85115860		19961221 <--
NO 9703814	A	19971013	NO 1997-3814		19970819 <--
NO 316724	B1	20040419			

PRIORITY APPLN. INFO.: JP 1995-354654 A 19951222
WO 1996-JP3722 W 19961220

AB Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4'-4''-fluorophenyl-2'-cyclopropyl-quinolin-3'-yl]-6-heptenoic acid (NK-104), or its salt or ester, of which the aqueous solution or dispersion has a pH of from 7 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. A pharmaceutical tablet contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropylmethyl cellulose 2.0, magnesium metasilicate aluminate 2.4, and magnesium stearate 1.2 mg.

IT 147511-69-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing quinolinheptenoic acid derivs. stabilized with basic agent)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT 147526-32-7 192565-91-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing quinolinheptenoic acid derivs. stabilized with basic agent)

RN 147526-32-7 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

RN 192565-91-6 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, potassium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● K

L10 ANSWER 13 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:727759 CAPLUS
DOCUMENT NUMBER: 138:314487
TITLE: Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. [Erratum to document cited in CA136:79688]
AUTHOR(S): Ohnaka, Keizo; Shimoda, Seiko; Nawata, Hajime; Shimokawa, Hiroaki; Kaibuchi, Kozo; Iwamoto, Yukihide; Takayanagi, Byoichi
CORPORATE SOURCE: Department of Geriatric Medicine, Kyushu University, Higashi-ku, Fukuoka, 812-8582, Japan
SOURCE: Biochemical and Biophysical Research Communications (2001), 287(5), 1167
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On page 337, in the author line, the affiliations of the last author were incorrectly represented. Ryoichi Takayanagi is associated with the Department of Geriatric Medicine and CREST, not with the Department of Medicine and Bioregulatory Science and CREST as printed.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts (Erratum))

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 14 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:796300 CAPLUS

DOCUMENT NUMBER: 139:127088

TITLE: Novel Statins: Pharmacological and Clinical Results

AUTHOR(S): Bolego, Chiara; Poli, Andrea; Cignarella, Andrea; Catapano, Alberico L.; Paoletti, Rodolfo

CORPORATE SOURCE: Nutrition Foundation of Italy, Milan, 20121, Italy

SOURCE: Cardiovascular Drugs and Therapy (2002), 16(3), 251-257
CODEN: CDTHET; ISSN: 0920-3206

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacol. profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P 450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

IT 147511-69-1, Pitavastatin
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. and clin. results of new statins)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:615881 CAPLUS
DOCUMENT NUMBER: 137:139496
TITLE: Process for producing (3R,5S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ester and derivatives
INVENTOR(S): Hara, Mari; Takuma, Yuki; Katsurada, Manabu; Hosokawa, Akemi; Matsumoto, Youichi; Kasuga, Yuzo; Watanabe, Naoyuki
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002063028	A1	20020815	WO 2002-JP835	20020201 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003137870	A	20030514	JP 2001-331480	20011029
CA 2437312	A1	20020815	CA 2002-2437312	20020201 <--
AU 2002228413	A1	20020819	AU 2002-228413	20020201 <--
AU 2002228413	B2	20070222		
JP 2002300897	A	20021015	JP 2002-25423	20020201 <--
JP 4000263	B2	20071031		
EP 1365029	A1	20031126	EP 2002-710461	20020201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1633502	A	20050629	CN 2002-807852	20020201
US 20040030139	A1	20040212	US 2003-629865	20030730
US 6965031	B2	20051115		
IN 2003CN01356	A	20051125	IN 2003-CN1356	20030828
PRIORITY APPLN. INFO.:			JP 2001-26316 A	20010202

JP 2001-331480 A 20011029
WO 2002-JP835 W 20020201

OTHER SOURCE(S): CASREACT 137:139496; MARPAT 137:139496

GI



I

AB A process for producing the title compound (I) and optically active derivs. with microorganism by fermentation was given. I is useful as serum cholesterol-reducing agent. Preparation of Et ester of I (3R, 5S-DOLE) and its derivs. 3S,5R-, 3S,5S-, and 3R,5R-DOLE with Saccharomycopsis fibuligera from 5-Mol, i.e. 5-(E)-7-[2-cyclopropyl-4-(fluorophenyl)-quinolin-3-yl]-5-hydroxy-3-oxohepto-6-enoic acid Et ester was shown.

IT 147511-69-1P 167073-19-0P
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(process for producing (3R,5S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ester and derivs.)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167073-19-0 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:437338 CAPLUS
DOCUMENT NUMBER: 138:66410
TITLE: Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin
AUTHOR(S): Kohno, Masakazu; Shinomiya, Kaori; Abe, Satomi; Noma, Takahisa; Kondo, Isao; Oshita, Akira; Takeuchi, Hiroto; Takagi, Yuichiro; Yukiiri, Kazushi; Mizushige, Katsufumi; Ohmori, Koji
CORPORATE SOURCE: Second Department of Internal Medicine, School of Medicine, Kagawa Medical University, Kagawa, 761-0793, Japan
SOURCE: Hypertension Research (2002), 25(2), 279-285
CODEN: HRESE4; ISSN: 0916-9636
PUBLISHER: Japanese Society of Hypertension
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The migration and proliferation of vascular smooth muscle cells (SMCs) are known to play roles in the pathogenesis of atherosclerosis. Therapy with a reductase inhibitor of 3-hydroxy-3 methylglutaryl CoA (HMG-CoA) (statin) produces significant alterations in various SMC functions. The objectives of the present study were to determine whether pitavastatin, a new chemical synthesized and powerful statin, can affect angiotensin II (Ang II)-
and platelet-derived growth factor (PDGF)-induced migration and proliferation of cultured rat vascular SMCs. The effect of pitavastatin on cell viability was also examined in these cells. Migration was evaluated by the Boyden's chamber method using microchemotaxis chambers. As expected, Ang II and PDGF BB potently stimulated cell migration in a concentration-dependent manner. Pitavastatin significantly inhibited Ang II (10-6 mol/L)-induced migration at the concns. of 10-8 and 10-7 mol/L. Pitavastatin also inhibited PDGF BB (1 ng/mL)-induced migration at concns. between 10-9 and 10-8 mol/L in a relatively concentration-dependent manner. This statin modestly but significantly inhibited Ang II (10-6 mol/L)- and PDGF BB (1 ng/mL)-induced DNA synthesis at concns. between 10-9 and 10-7 mol/L. In addition, pitavastatin clearly inhibited Ang II (10-6 mol/l)- and PDGF BB (1 ng/mL)-induced increases of cell number at concns. between 10-9 and 10-7mol/l. Pitavastatin did not affect lactate dehydrogenase release from these cells at the concns. used in this experiment
In a trypan blue exclusion test, dead cells stained with trypan blue were not found 24 h after treatment with 10-9, 10-8 or 10-7 mol/L of pitavastatin. These findings suggest that pitavastatin suppresses the migration and proliferation stimulated by Ang II and PDGF BB without affecting cell viability. Pitavastatin may exert an

anti-atherogenic effect, in part, through these mechanisms.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:642388 CAPLUS

DOCUMENT NUMBER: 138:180063

TITLE: Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin

AUTHOR(S): Igel, Michael; Sudhop, Thomas; von Bergmann, Klaus

CORPORATE SOURCE: Department of Clinical Pharmacology, University of Bonn, Bonn, Germany

SOURCE: Journal of Clinical Pharmacology (2002), 42(8), 835-845
CODEN: JCPCBR; ISSN: 0091-2700

PUBLISHER: Sage Publications

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the Western world, with hypercholesterolemia as the major risk factor. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors represent the most efficient drugs for the treatment of hypercholesterolemia. They lower plasma cholesterol due to the inhibition of endogenous cholesterol synthesis in the liver and subsequent increased expression of low-d. lipoprotein (LDL) receptors, resulting in an up-regulated catabolic rate for plasma LDL. The beneficial effect of statins on the incidence of CHD was clearly demonstrated in several large-scale clin. trials. Currently, five statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) are available, and two novel compds. (pitavastatin, rosuvastatin) are undergoing clin. investigation. To point out potential mechanisms leading to increased toxicity and to compare the novel statins with the established ones, this article summarizes their pharmacol. data since the prevalence of adverse events can be explained at least in part by their pharmacokinetic differences.

IT 147511-69-1, Pitavastatin

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins), including rosuvastatin and pitavastatin)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 117 THERE ARE 117 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:832618 CAPLUS

DOCUMENT NUMBER: 137:337790

TITLE: Preparation of 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid as remedial agent for glomerular disease

INVENTOR(S): Nakagawa, Takashi; Suda, Makoto; Yamauchi, Youichi

PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085363	A1	20021031	WO 2002-JP3870	20020418 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002251483	A1	20021105	AU 2002-251483	20020418 <--
EP 1386608	A1	20040204	EP 2002-720493	20020418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040116468	A1	20040617	US 2003-474194	20031016
PRIORITY APPLN. INFO.:			JP 2001-121058	A 20010419
			JP 2001-361257	A 20011127

GI



I

AB Disclosed is a preventive or remedy for glomerular diseases which contains as the active ingredient the compound represented by the following formula (I) or a salt of the compound The preventive or remedy is useful as a preventive or remedy for various glomerular diseases including IgA kidney disease, glomerulosclerosis, membranous nephropathy, membranous proliferative nephritis, and chronic glomerulonephritis. The compound I is known to possess excellent HMG-CoA reductase inhibitory activity (no data). Thus, calcium bis[(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (II) was prepared via conversion of 2-amino-4'-fluorobenzophenone into Me 3-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate by the known procedures. II showed IC50 of 22.4 μM for inhibiting the production of phosphatidylinositol 4-phosphate (PIP) stimulated by TGF-β1 in human glomerular interstitial cell CryoNHMC (mesangium cell).

IT 147511-69-1P, (+)-(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid
147526-32-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [cyclopropyl(fluorophenyl)quinolyl]hydroxyheptenoic acid as
remedial agent for glomerular diseases)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 147526-32-7 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:392219 CAPLUS
DOCUMENT NUMBER: 136:406945
TITLE: Methods for in vivo drug delivery based on monitoring blood flow parameters
INVENTOR(S): Kensey, Kenneth R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 727,950.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020061835	A1	20020523	US 2001-828761	20010409 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
US 6322524	B1	20011127	US 1999-439795	19991112 <--
US 6322525	B1	20011127	US 2000-501856	20000210 <--

PATENT NO. KIND DATE APPLICATION NO. DATE

NO 2000000944 A 20000225 NO 2000-944 20000225 <--
MX 200002073 A 20010821 MX 2000-2073 20000228 <--
US 6428488 B1 20020806 US 2000-615340 20000712 <--
WO 2002009583 A2 20020207 WO 2001-US23696 20010730 <--
WO 2002009583 A3 20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002043806 A2 20020606 WO 2001-US44352 20011127 <--
WO 2002043806 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002026986 A 20020611 AU 2002-26986 20011127 <--
US 20020088953 A1 20020711 US 2001-33841 20011227 <--
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207 <--
WO 2002079778 A3 20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 20020184941 A1 20021212 US 2002-156165 20020528 <--
US 6571608 B2 20030603

PRIORITY APPLN. INFO.:

US 1997-919906 A2 19970828
US 1999-439795 A2 19991112
US 2000-501856 A2 20000210
US 2000-628401 A2 20000801
US 2000-727950 A2 20001201
US 1997-966076 A 19971107
WO 1998-US17657 W 19980826
US 2000-615340 A3 20000712
US 2000-228612P P 20000828
US 2001-789350 B2 20010221
US 2001-819924 A 20010328
US 2001-828761 A 20010409
US 2001-839785 A 20010420
US 2001-841389 A 20010424
US 2001-897164 A3 20010702
WO 2001-US44352 W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as

peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for in vivo drug delivery based on monitoring blood flow parameters)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 20 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:727843 CAPLUS

DOCUMENT NUMBER: 138:348132

TITLE: HMG-CoA reductase inhibition prevent vascular diseases by specifically targeting the transcription

AUTHOR(S): Morikawa, Shigeru; Hamakubo, Takao; Kodama, Tatsuhiko

CORPORATE SOURCE: Graduate School of Life and Science and Engineering, Tokyo Institute of Technology, Japan

SOURCE: Molecular Medicine (Tokyo, Japan) (2002), 39(7), 842-846
CODEN: MOLMEL; ISSN: 0918-6557

PUBLISHER: Nakayama Shoten

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review. HMG-CoA reductase inhibitors statins are wildly used as anticholesteremics, and their mechanisms are related with transcription factor SREBP and LDL receptors. Pitavastatin is an example is used in this review to demonstrate the clin. use.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibition prevent vascular diseases by specifically targeting the transcription)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 21 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319495 CAPLUS
DOCUMENT NUMBER: 138:343864
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078517	A1	20030424	US 2001-839785	20010420
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
US 6322524	B1	20011127	US 1999-439795	19991112 <--
US 6322525	B1	20011127	US 2000-501856	20000210 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
MX 200002073	A	20010821	MX 2000-2073	20000228 <--
US 6428488	B1	20020806	US 2000-615340	20000712 <--
WO 2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO 2002009583	A3	20020425		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002043806	A2	20020606	WO 2001-US44352	20011127 <--
WO 2002043806	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002026986	A	20020611	AU 2002-26986	20011127 <--
US 20020088953	A1	20020711	US 2001-33841	20011227 <--
US 6624435	B2	20030923		
WO 2002079778	A2	20021010	WO 2002-US3984	20020207 <--
WO 2002079778	A3	20030710		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20020184941	A1	20021212	US 2002-156165	20020528 <--
US 6571608	B2	20030603		

PRIORITY APPLN. INFO.:

US 1997-919906	A2 19970828
US 1999-439795	A2 19991112
US 2000-501856	A2 20000210
US 2000-628401	A2 20000801
US 2000-727950	B2 20001201
US 2001-819924	A2 20010328
US 1997-966076	A 19971107
WO 1998-US17657	W 19980826
US 2000-615340	A3 20000712
US 2000-228612P	P 20000828
US 2001-789350	B2 20010221
US 2001-828761	A 20010409
US 2001-839785	A 20010420
US 2001-841389	A 20010424
US 2001-897164	A3 20010702
WO 2001-US44352	W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least 1 drug. Agents effective to regulate at least 1 of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo delivery methods and compns.)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 22 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:185688 CAPLUS
DOCUMENT NUMBER: 136:252567
TITLE: Methods for drug administration and distribution based on monitoring blood viscosity and other parameters for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020032149	A1	20020314	US 2001-841389	20010424 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
US 6322524	B1	20011127	US 1999-439795	19991112 <--
US 6322525	B1	20011127	US 2000-501856	20000210 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
MX 200002073	A	20010821	MX 2000-2073	20000228 <--
US 6428488	B1	20020806	US 2000-615340	20000712 <--
WO 2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO 2002009583	A3	20020425		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20020088953 A1 20020711 US 2001-33841 20011227 <--
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207 <--
WO 2002079778 A3 20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 20020184941 A1 20021212 US 2002-156165 20020528 <--
US 6571608 B2 20030603

PRIORITY APPLN. INFO.:

US 1997-919906	A2	19970828
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
US 2000-727950	A2	20001201
US 2001-819924	A2	20010328
US 1997-966076	A	19971107
WO 1998-US17657	W	19980826
US 2000-615340	A3	20000712
US 2000-228612P	P	20000828
US 2001-789350	B2	20010221
US 2001-828761	A	20010409
US 2001-839785	A	20010420
US 2001-841389	A	20010424
US 2001-897164	A3	20010702

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being, i.e., a human, over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream. For example, when blood viscosity is a blood flow parameter monitored, an agent is selected from i.v. diluents, red blood cell deformability agents, antiurea agents, oral contraceptives, antidiabetic agents, antiarrhythmics, antihypertensives, antihyperlipidemics, antiplatelet agents, appetite suppressants, antiobesity agents, blood modifiers, smoking deterrent agents, and nutritional supplements.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apparatus and methods for monitoring blood viscosity and other parameters
in drug delivery for diagnostics and treatment)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 23 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:440183 CAPLUS
DOCUMENT NUMBER: 138:100712
TITLE: Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia
AUTHOR(S): Aoki, Taro; Yoshinaka, Yasunobu; Yamazaki, Hiroyuki; Suzuki, Hideo; Tamaki, Taro; Sato, Fumiyasu; Kitahara, Masaki; Saito, Yasushi
CORPORATE SOURCE: Pharmaceutical Division, Tokyo Research Laboratories, Kowa Company, Ltd., 2-17-43, Tokyo, Higashimurayama, 189-0022, Japan
SOURCE: European Journal of Pharmacology (2002), 444(1-2), 107-113
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The triglyceride-lowering effect of pitavastatin, a potent 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, was investigated in a rat model of postprandial lipemia. Plasma triglyceride levels started to increase 4 h after the fat load, reached the maximum at 6 h and then gradually decreased. A single dose of pitavastatin (1 mg/kg) significantly suppressed chylomicron-triglyceride secretion into the lymph by 40% and delayed the elevation of plasma triglyceride. Pitavastatin at 1 mg/kg decreased the 6-h plasma triglyceride levels by 53% and at 0.5 mg/kg decreased the 0-12 h area under the curve (AUC) of triglyceride levels by 56%. Atorvastatin also caused decreases, but to a lesser extent. Pitavastatin, and atorvastatin to a lesser extent, reduced the activity of the intestinal microsomal triglyceride transfer protein (MTP) at 6 h. These results suggested that a single dose of pitavastatin lowered postprandial triglyceride levels in rats by decreasing chylomicron-triglyceride secretion, probably through a reduction of intestinal MTP activity and triglyceride droplet formation in the endoplasmic reticulum.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:208097 CAPLUS
DOCUMENT NUMBER: 134:247262
TITLE: Phosphodiesterase inhibitor-hypolipidemic agent combination for the treatment of sexual dysfunction
INVENTOR(S): Bischoff, Erwin; Bischoff, Hilmar; Giuliano, Francois
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019357	A2	20010322	WO 2000-EP8836	20000911 <--
WO 2001019357	A3	20010927		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19944161	A1	20010322	DE 1999-19944161	19990915 <--
CA 2386583	A1	20010322	CA 2000-2386583	20000911 <--
AU 2000076524	A	20010417	AU 2000-76524	20000911 <--
EP 1216039	A2	20020626	EP 2000-965957	20000911 <--
EP 1216039	B1	20050316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES 2239042	T3	20050916	ES 2000-965957	20000911
US 20060189624	A1	20060824	US 2006-347741	20060203

PRIORITY APPLN. INFO.:
DE 1999-19944161 A 19990915
WO 2000-EP8836 W 20000911
US 2002-70963 B1 20020628

OTHER SOURCE(S): MARPAT 134:247262

AB A combination preparation is disclosed for the treatment of sexual dysfunction in men or women containing at least one active ingredient A and one active ingredient B as pharmaceutically active ingredients, in which the active ingredient A is a phosphodiesterase inhibitor, preferably a cGMP phosphodiesterase inhibitor and the active ingredient B a lipid-reducing agent. Both the active ingredients A and B can be administered

simultaneously or at alternate intervals, i.e., as a functional unit or separated from each other.

IT 141750-63-2D, Itavastatin, esters and tautomers
147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase inhibitor-hypolipidemic agent combination for the treatment of sexual dysfunction)

RN 141750-63-2 CAPLUS
CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 25 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:813874 CAPLUS
DOCUMENT NUMBER: 137:311199
TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes
INVENTOR(S): Gougoutas, Jack Z.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408 <--
WO 2002083066	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444481	A1	20021024	CA 2002-2444481	20020408 <--
AU 2002254567	A1	20021028	AU 2002-254567	20020408 <--
AU 2002254567	B2	20071011		
US 20030064935	A1	20030403	US 2002-117914	20020408
US 6774112	B2	20040810		
EP 1385856	A2	20040204	EP 2002-723801	20020408
EP 1385856	B1	20060222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004536047	T	20041202	JP 2002-580871	20020408
AT 318272	T	20060315	AT 2002-723801	20020408
ES 2258141	T3	20060816	ES 2002-723801	20020408
HU 2006000232	A2	20060828	HU 2006-232	20020408
AU 2008200159	A1	20080207	AU 2008-200159	20080111

PRIORITY APPLN. INFO.:			
US 2001-283097P	P	20010411	
AU 2002-254567	A3	20020408	
WO 2002-US11066	W	20020408	

OTHER SOURCE(S): MARPAT 137:311199
GI



I

AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or
(L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney)

inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF2, R2, R2a, R3 = H) was prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the crystalline 1:1 complex.

IT 141750-63-2, Nisvastatin 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 141750-63-2 CAPLUS
CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 26 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:868726 CAPLUS
DOCUMENT NUMBER: 137:358160
TITLE: Pharmaceutical composition comprising a HMG-CoA reductase inhibitor
INVENTOR(S): Hedge, Deepak; Kulkarni, Sushrut
PATENT ASSIGNEE(S): Biochemie Gesellschaft m.b.H., Austria
SOURCE: PCT Int. Appl., 13 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089788	A2	20021114	WO 2002-EP4891	20020503 <--
WO 2002089788	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
TW 239839	B	20050921	TW 2002-91109135	20020502
AU 2002310798	A1	20021118	AU 2002-310798	20020503 <--
EP 1392277	A2	20040303	EP 2002-735331	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040167085	A1	20040826	US 2004-476816	20040413
US 6911472	B2	20050628		

PRIORITY APPLN. INFO.:	GB 2001-11077	A	20010504
	WO 2002-EP4891	W	20020503

AB A pharmaceutical composition comprising an HMG-CoA reductase inhibitor, i.e., a statin, as an active ingredient, and an aminosugar, as a pH adjusting (basifying) agent, is described. Compns. comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivs. or HMG-CoA reductase inhibitors, and sugar derivs., and comprising germs for a koji-making raw material and monacolin K, are excluded. For example, tablets were obtained containing pravastatin sodium 10.00%, lactose (filler) 68.20%, microcryst. cellulose (filler) 13.50%, polyvinylpyrrolidone (binder) 0.50%, croscarmellose sodium (disintegrant) 6.00%, Mg stearate (lubricant) 1.00%, and Meglumine (pH adjusting agent) 0.80%. Tablets were stable for > 1 mo under normal environment humidity conditions.

IT 141750-63-2, Nisvastatin 147511-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of tablets of HMG-CoA reductase inhibitors containing aminosugar as pH adjusting agent)

RN 141750-63-2 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 27 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:484862 CAPLUS
DOCUMENT NUMBER: 137:41779
TITLE: Nutritional supplements for stimulating bone growth
INVENTOR(S): Mundy, Gregory R.; Garrett, I. Ross; Gutierrez, Gloria E.
PATENT ASSIGNEE(S): Osteoscreen, Inc., USA
SOURCE: U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 488,380.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6410521	B1	20020625	US 2000-541943	20000403 <--
US 6080779	A	20000627	US 1998-96957	19980612 <--
US 6376476	B1	20020423	US 2000-488380	20000120 <--
WO 2001074180	A1	20011011	WO 2001-US40421	20010402 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267641	A1	20030102	EP 2001-927431	20010402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

US 1998-96631	A2	19980612
US 1998-96957	A2	19980612
US 2000-488380	A2	20000120
US 1996-32893P	P	19961213
US 1997-989862	A2	19971212
US 2000-541943	A	20000403
WO 2001-US40421	W	20010402

AB A food or food supplement which comprises a compound that enhances bone growth in vertebrates is described wherein the food or foodstuff is formulated so as to provide the desired bone growth enhancing effect. The

methods of the invention use red yeast rice or a statin compound

IT 141750-63-2 147511-69-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements for stimulating bone growth)

RN 141750-63-2 CAPLUS
CN 2H-Pyran-2-one, 6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:428760 CAPLUS
DOCUMENT NUMBER: 137:24314
TITLE: Methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth; Hokanson, Charles
PATENT ASSIGNEE(S): Visco Technologies, Inc., USA; Rheologics, Inc.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043806	A2	20020606	WO 2001-US44352	20011127 <--
WO 2002043806	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
US 20020061835	A1	20020523	US 2001-828761	20010409 <--
US 20030078517	A1	20030424	US 2001-839785	20010420
AU 2002026986	A	20020611	AU 2002-26986	20011127 <--

PRIORITY APPLN. INFO.:		
US 1997-966076	A	19971107
US 2000-727950	A	20001201
US 2001-819924	A	20010328
US 2001-828761	A	20010409
US 2001-839785	A	20010420
US 1997-919906	A	19970828
WO 1998-US17657	W	19980826
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
WO 2001-US44352	W	20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 29 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:682421 CAPLUS
DOCUMENT NUMBER: 138:280954
TITLE: HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes
AUTHOR(S): Sone, Hirohito; Takahashi, Akimitsu; Shimano, Hitoshi; Ishibashi, Shun; Yoshino, Gen; Morisaki, Nobuhiro; Saito, Yasushi; Kawazu, Shoji; Teramoto, Tamio; Fujita, Toshiro; Shiba, Teruo; Iwamoto, Yasuhiko; Kuzuya, Nobuaki; Akanuma, Yasuo; Yamada, Nobuhiro
CORPORATE SOURCE: Institute of Clinical Medicine, Department of Internal Medicine (Endocrinology/Metabolism), University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan
SOURCE: Life Sciences (2002), 71(20), 2403-2412
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Patients with type 2 diabetes are known to have abnormalities in their remnant metabolism and low d. lipoprotein (LDL) subfraction pattern, with a preponderance of small dense LDL. The effects of pitavastatin, a newly synthesized 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, on lipoprotein profiles in patients with type 2 diabetes were determined Thirty-three patients were treated with pitavastatin with a daily dose of 2 mg for 8 wk. After treatment, triglyceride, total and LDL cholesterol were significantly reduced by 28.7 ± 36.7%, 25.2 ± 14.3% and 36.1 ± 14.3%, resp. Remnant-like particle cholesterol (RLP-C), an independent risk factor for CAD which is known to be elevated in diabetic patients, was also significantly reduced (-30.9 ± 30.5%) by the treatment and this decrease correlated well with the decrease in triglyceride level. The proportion of small dense LDL, which is known for its atherogenisity, decreased from 29.9 ± 26.2% to 19.7 ± 22.7% and the mean LDL particle size significantly increased from 26.36 ± 1.13 nm to 27.10 ± 1.36 nm. Pitavastatin, which is known to improve triglyceride levels and cholesterol levels, also improves RLP-C level and LDL subfraction profiles, and this in turn may reduce the cardiovascular risk in patients with type 2 diabetes and dyslipidemia.
IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor decreases small dense LDL and remnant-like

particle cholesterol in patients with type-2 diabetes)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:240538 CAPLUS
DOCUMENT NUMBER: 136:268166
TITLE: Spray drying process for preparation of fenofibrate compositions
INVENTOR(S): Pace, Gary; Mishra, Awadhesh K.; Snow, Robert A.; Parikh, Indu; Guivarc'h, Pol-Henri
PATENT ASSIGNEE(S): RTP Pharma Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024169	A1	20020328	WO 2001-US12746	20010420 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2423335	A1	20020328	CA 2001-2423335	20010420 <--
AU 2001062945	A	20020402	AU 2001-62945	20010420 <--
US 20020056206	A1	20020516	US 2001-838593	20010420 <--
US 6696084	B2	20040224		
CA 2440355	A1	20020906	CA 2001-2440355	20010420 <--
WO 2002067901	A1	20020906	WO 2001-US12747	20010420 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001259099	A1	20020912	AU 2001-259099	20010420	<--
US 20020161032	A1	20021031	US 2001-838583	20010420	<--
US 6534088	B2	20030318			
EP 1322289	A1	20030702	EP 2001-937182	20010420	
EP 1322289	B1	20070725			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EP 1361867	A1	20031119	EP 2001-932584	20010420	
EP 1361867	B1	20070321			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 1505502	A	20040616	CN 2001-823164	20010420	
JP 2004523552	T	20040805	JP 2002-567269	20010420	
NZ 525306	A	20041126	NZ 2001-525306	20010420	
NZ 527408	A	20050429	NZ 2001-527408	20010420	
AT 357216	T	20070415	AT 2001-932584	20010420	
AT 367802	T	20070815	AT 2001-937182	20010420	
ES 2284646	T3	20071116	ES 2001-932584	20010420	
US 20040086571	A1	20040506	US 2003-388597	20030317	
HK 1061357	A1	20071102	HK 2004-102918	20040426	
AU 2007201953	A1	20070524	AU 2007-201953	20070501	

PRIORITY APPLN. INFO.:	US 2000-234186P	P	20000920
	US 2000-241761P	P	20001020
	US 2001-270157P	P	20010222
	AU 2001-55515	T0	20010420
	US 2001-838583	A3	20010420
	WO 2001-US12746	W	20010420
	WO 2001-US12747	W	20010420

AB The present invention relates to a novel spray drying process for the preparation of pharmaceutical compns. containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compns. prepared according to this process and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compns. The powdered compns. and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally. An admixt. of 3% Lipoid E80 as the surfactant and 10% fenofibrate is homogeneously dispersed in pH 8.0 10 mM aqueous phosphate buffer by using a high-shear mixer for 30 min. Mannitol (10%) is then added and the admixt. is heated to 95° during continuous high shear mixing. The heated suspension is then homogenized for 10 batch volume cycles or passes by using a microfluidizer to form a heated homogenate containing the drug. After 10 passes, the heated homogenate is then spray dried to produce a dried powder containing Lipoid E80-stabilized microparticles of fenofibrate in mannitol.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spray drying for preparation of fenofibrate compns.)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:171683 CAPLUS
DOCUMENT NUMBER: 136:205466
TITLE: Medicinal compositions containing HMG-CoA reductase inhibitors and angiotensin II receptor antagonists for preventing or treating heart failure
INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao, Chia-Ling; Chu, Chia-Wei
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017913	A1	20020307	WO 2001-JP7437	20010829 <--
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001084413	A5	20020313	AU 2001-84413	20010829 <--
JP 2002145770	A	20020522	JP 2001-259399	20010829 <--
CA 2420844	A1	20030228	CA 2001-2420844	20010829
EP 1314425	A1	20030528	EP 2001-963398	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 20030181500	A1	20030925	US 2003-374171	20030226
US 20050059720	A1	20050317	US 2004-977645	20041029

PRIORITY APPLN. INFO.:		
JP 2000-260949	A	20000830
WO 2001-JP7437	W	20010829
US 2003-374171	A3	20030226

AB Disclosed are medicinal compns. comprising an HMG-CoA reductase inhibitor selected from the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of pravastatin 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing HMG-CoA reductase inhibitors and angiotensin
II receptor antagonists for preventing or treating heart failure)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 32 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1007596 CAPLUS
DOCUMENT NUMBER: 140:65183
TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
INVENTOR(S): Chen, Feng-Jing; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Pat. Appl. 2002 32,171.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20030235595	A1	20031225	US 2003-397969	20030325	
US 6267985	B1	20010731	US 1999-345615	19990630	<--
US 6309663	B1	20011030	US 1999-375636	19990817	<--
US 20010024658	A1	20010927	US 2000-751968	20001229	<--
US 6458383	B2	20021001			
US 20020032171	A1	20020314	US 2001-877541	20010608	<--
US 6761903	B2	20040713			
WO 2004087052	A2	20041014	WO 2004-US9120	20040325	
WO 2004087052	A3	20041118			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1999-345615	A2 19990630
US 1999-375636	A2 19990817
US 2000-751968	A2 20001229

US 2001-877541	A2	20010608
WO 2000-US18807	A	20000710
US 2003-397969	A	20030325

AB The present invention relates to oral pharmaceutical compns. and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compns. of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compns. provided.

IT 147511-69-1, Pitavastatin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral composition containing triglyceride and surfactants for improved delivery of hydrophobic drugs)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 33 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2003:120064 CAPLUS
DOCUMENT NUMBER:	139:223407
TITLE:	Preclinical pharmacokinetics of statins
AUTHOR(S):	Reinoso, R. F.; Navarro, Sanchez A.; Garcia, M. J.; Prous, J. R.
CORPORATE SOURCE:	Prous Science, Barcelona, Spain
SOURCE:	Methods and Findings in Experimental and Clinical Pharmacology (2002), 24(9), 593-613 CODEN: MFEPDX; ISSN: 0379-0355
PUBLISHER:	Prous Science
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review. This review summarizes the pharmacokinetic properties of HMG-CoA reductase inhibitors (or statins) reported in animals. Lovastatin and simvastatin are administered as lactone prodrugs in contrast to other statins, which are generally formulated in the pharmacol. active hydroxy acid form. Pharmacokinetics vary with the statin and animal species considered. Oral absorption is rapid and the bioavailability low due to an extensive first-pass metabolism Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).

Plasma protein binding is high for all statins (> 95%) except pravastatin (60%). Regardless of the dosing schedule (single or multiple), animal species and statin, the highest tissue levels are found in the liver-the target organ. Elimination is rapid with metabolism being the main elimination route for all statins, except for pitavastatin, which is only slightly metabolized, and pravastatin, which aside from metabolism is also eliminated by renal excretion. Statins undergo enterohepatic circulation and are recovered mainly in feces via bile, the extent of which is species-dependent. Metabolism varies with the statin and animal species, particularly the β-oxidation of the dihydroxy heptanoic side chain that occurs primarily in rodents.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preclin. pharmacokinetics of statins)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:562226 CAPLUS
DOCUMENT NUMBER: 138:100247
TITLE: Future prospects of new statins
AUTHOR(S): Bujo, Hideaki
CORPORATE SOURCE: Graduate School of Medicine, Chiba University, Japan
SOURCE: Chiryogaku (2002), 36(5), 502-505
CODEN: CHRYDT; ISSN: 0386-8109
PUBLISHER: Raifu Saiensu Shuppan K.K.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review. Future prospects of new hypolipemic agents statins such as pravastatin, pitavastatin, and rosuvastatin etc. as NADPH-hydroxymethylglutaryl-CoA reductase inhibitors are reviewed.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(future prospects of new statins)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



L10 ANSWER 35 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:428761 CAPLUS
DOCUMENT NUMBER: 137:11000
TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction
INVENTOR(S): Sahota, Pritam Singh
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129 <--
WO 2002043807	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2430924	A1	20020606	CA 2001-2430924	20011129 <--
AU 2002026365	A5	20020611	AU 2002-26365	20011129 <--
EP 1353727	A2	20031022	EP 2001-995680	20011129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514703	T	20040520	JP 2002-545776	20011129
US 20020107236	A1	20020808	US 2001-8445	20011203 <--
US 20040087484	A1	20040506	US 2003-433189	20030624

PRIORITY APPLN. INFO.: US 2000-250540P P 20001201
WO 2001-EP13976 W 20011129

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT 147511-69-1, PITaVASTATIN
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing angiotensin receptor blockers for

treating sexual dysfunction)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 36 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:184896 CAPLUS
DOCUMENT NUMBER: 136:236854
TITLE: Medicinal compositions for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors
INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020009	A1	20020314	WO 2001-JP7438	20010829 <--
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001082541	A	20020322	AU 2001-82541	20010829 <--
CA 2420951	A1	20030228	CA 2001-2420951	20010829
EP 1314423	A1	20030528	EP 2001-961177	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2003001728	A2	20030828	HU 2003-1728	20010829
HU 2003001728	A3	20040528		
NZ 524406	A	20040625	NZ 2001-524406	20010829
BR 2001013523	A	20040629	BR 2001-13523	20010829
RU 2246302	C2	20050220	RU 2003-105835	20010829
US 20020055533	A1	20020509	US 2001-943712	20010831 <--
JP 2002145774	A	20020522	JP 2001-262600	20010831 <--
IN 2003KN00186	A	20050311	IN 2003-KN186	20030213
ZA 2003001543	A	20040609	ZA 2003-1543	20030225
NO 2003000946	A	20030408	NO 2003-946	20030228
MX 2003PA01857	A	20030604	MX 2003-PA1857	20030228
US 20040092571	A1	20040513	US 2003-702930	20031105
PRIORITY APPLN. INFO.:			JP 2000-265082 A	20000901

US 2000-230601P	P	20000906
WO 2001-JP7438	W	20010829
US 2001-943712	B1	20010831

AB Disclosed are medicinal compns. for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an HMG-CoA reductase inhibitor either at the same time or sep. after a definite period of time. Blood lipid-lowering effect of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and pravastatin 3 mg/kg in hamsters was examined Also, tablet containing I 30, sodium pravastatin 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 37 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:15391 CAPLUS
DOCUMENT NUMBER:	136:335067
TITLE:	Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARα/RXRα and Decrease the Transactivation of NFκB
AUTHOR(S):	Inoue, Ikuo; Itoh, Fumiaki; Aoyagi, Shigemi; Tazawa, Shigeki; Kusama, Hiroshi; Akahane, Masuo; Mastunaga, Toshiyuki; Hayashi, Kenji; Awata, Takuya; Komoda, Tugikazu; Katayama, Sigehiro
CORPORATE SOURCE:	Fourth Department of Internal Medicine, Saitama Medical School, Moroyama, Iruma-gun, Saitama, 350-0495, Japan
SOURCE:	Biochemical and Biophysical Research Communications (2002), 290(1), 131-139 CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER:	Academic Press
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB In this study, we used a coactivator-dependent receptor-ligand interaction assay (CARLA), which is a semifunctional in vitro assay, to determine whether
hypolipidemic drugs are ligands for the three peroxisome

proliferator-activated receptor isotypes (PPARα, δ, and γ). We also evaluated the transcriptional activities of the three PPAR isotypes by transient transfection assays. We found that bezafibrate was a ligand for PPARα, δ, and γ in the CARLA and that bezafibrate induced transcriptional activation of PPARα/RXRα, PPARδ/RXRα, and PPARγ/RXRα. Although the 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors cerivastatin, fluvastatin, and pitavastatin were not ligands for these three nuclear receptors in the CARLA, they induced transcriptional activation of PPARα/RXRα, PPARδ/RXRα, and PPARγ2/RXRα. Moreover, cerivastatin, fluvastatin, and pitavastatin synergistically and dose-dependently increased the transcriptional activation of PPARα/RXRα induced by bezafibrate. In addition, the cerivastatin-induced transcriptional activation of PPARα/RXRα was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1). Moreover, concomitant administration of statins and fibrates also decreased the transactivation of nuclear factor κB (NFκB) and the activation of NFκB by mitogen-activated protein kinase kinase (MEKK) also decreased the transactivation of PPARα/RXRα. (c) 2002 Academic Press.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 38 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:626303 CAPLUS
DOCUMENT NUMBER: 136:318597
TITLE: Statin and smooth muscle cell function
AUTHOR(S): Kitahara, Masaki
CORPORATE SOURCE: Pharmaceutical Research Department, Biological Research Lab., Nissan Chemical Industries, Ltd., 349-0294, Japan
SOURCE: Cell (Tokyo, Japan) (2001), 33(9), 348-351
CODEN: SAIBD8; ISSN: 0386-4766
PUBLISHER: Nyu Saiensusha
DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review, discussing the pharmacol. of statin derivs. (e.g. pitavastatin) as HMG-CoA reductase inhibitors on vascular smooth muscle function for treatment of cardiovascular diseases.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of statin derivs. and vascular smooth muscle cell function)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 39 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:597839 CAPLUS

DOCUMENT NUMBER: 135:185458

TITLE: TNF-α inhibitors containing combination of insulin resistance-ameliorating agents with HMG-CoA reductase inhibitors

INVENTOR(S): Sugiyama, Yasuo; Odaka, Hiroyuki; Naruo, Ken-ichi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058491	A1	20010816	WO 2001-JP880	20010208 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2399463	A1	20010816	CA 2001-2399463	20010208 <--
AU 2001032244	A5	20010820	AU 2001-32244	20010208 <--
EP 1254667	A1	20021106	EP 2001-904344	20010208 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2001294537	A	20011023	JP 2001-33804	20010209 <--
US 20030060488	A1	20030327	US 2002-203300	20020809

PRIORITY APPLN. INFO.: JP 2000-38265 A 20000210
WO 2001-JP880 W 20010208

OTHER SOURCE(S): MARPAT 135:185458

AB Disclosed is a TNF-α inhibitor comprising a combination of an insulin resistance-ameliorating agent with an HMG-CoA reductase inhibitor which is useful as a preventive or a remedy for inflammatory diseases, etc. A tablet containing pioglitazone hydrochloride 15 mg and a tablet containing sodium pravastatin 5 mg were applied to a patient with inflammatory disease to examine the serum TNF-α contents.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-α inhibitors containing combination of insulin resistance-ameliorating agents with HMG-CoA reductase inhibitors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 40 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:283949 CAPLUS
DOCUMENT NUMBER: 134:311218
TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors
INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002 <--
WO 2001027107	A3	20020124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870		B1	20050503	US 2000-669298	20000925
CA 2388813		A1	20010419	CA 2000-2388813	20001002 <--
EP 1224183		A2	20020724	EP 2000-968723	20001002 <--
EP 1224183		B1	20051228		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014725		A	20030617	BR 2000-14725	20001002
HU 2003000195		A2	20030728	HU 2003-195	20001002
HU 2003000195		A3	20030929		
JP 2003527331		T	20030916	JP 2001-530325	20001002
NZ 517668		A	20040924	NZ 2000-517668	20001002
AT 314364		T	20060115	AT 2000-968723	20001002
ES 2254236		T3	20060616	ES 2000-968723	20001002
IN 2002MN00354		A	20050318	IN 2002-MN354	20020322
ZA 2002002479		A	20040727	ZA 2002-2479	20020327
MX 2002PA03626		A	20030922	MX 2002-PA3626	20020410
NO 2002001717		A	20020610	NO 2002-1717	20020411 <--
US 20050137216		A1	20050623	US 2005-46993	20050131
US 7326705		B2	20080205		
PRIORITY APPLN. INFO.:				US 1999-158755P	P 19991012
				US 2000-669298	A3 20000925
				WO 2000-US27461	W 20001002

OTHER SOURCE(S): MARPAT 134:311218

GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 41 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:813924 CAPLUS
DOCUMENT NUMBER: 137:311200
TITLE: Preparation of 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV
INVENTOR(S): Sulsky, Richard B.; Robl, Jeffrey A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083128	A1	20021024	WO 2002-US10936	20020405 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020183367	A1	20021205	US 2002-107279	20020326 <--
US 6573287	B2	20030603		
CA 2444465	A1	20021024	CA 2002-2444465	20020405 <--
AU 2002254557	A1	20021028	AU 2002-254557	20020405 <--
AU 2002254557	B2	20070118		
EP 1377288	A1	20040107	EP 2002-723791	20020405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532220	T	20041021	JP 2002-580932	20020405
HU 2004001423	A2	20041129	HU 2004-1423	20020504

PRIORITY APPLN. INFO.:
US 2001-283438P P 20010412
WO 2002-US10936 W 20020405

OTHER SOURCE(S): MARPAT 137:311200
GI



I



II

AB The invention describes dipeptidyl peptidase IV (DP 4) inhibiting compds. I [n is 0 or 1; X is H or CN; Y is N, NH or O; Z is CH2 when Y is O or NH, with Y-Z forming a single bond, and Z is CH when Y is N, with Y-Z forming a double bond; R1-R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, bicycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R1 may combine with R3 or R4 to form a ring (CR5R6)2-6 or (CR7R8)3-6, resp., where R5-R8 = H, OH, alkoxy, alkyl, aryl, etc.] and their pharmaceutically-acceptable salts or prodrug esters. A method is also provided for treating diabetes and related diseases, employing a DP 4 inhibitor I, optionally in combination with other therapeutic agents, including an antidiabetic, hypolipidemic, or anti-obesity agent. Thus, coupling of sultam-protected 1,2-pyrazoline-3-carboxamide with (S)-N-(tert-butoxycarbonyl)cyclohexylglycine (HOAt, Et3N, and EDAC in CH2Cl2), followed by sultam cleavage with methanolic ammonia, amide conversion to nitrile using imidazole, and deprotection, afforded II.TFA.

IT 147511-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid modulating agent; preparation of oxazoline and pyrazoline-based inhibitors of dipeptidyl peptidase IV)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 42 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:575765 CAPLUS
DOCUMENT NUMBER: 137:140435
TITLE: Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020103242	A1	20020801	US 2001-21667	20011029 <--
US 6713508	B2	20040330		
CA 2427610	A1	20020808	CA 2001-2427610	20011026 <--
WO 2002060434	A2	20020808	WO 2001-US49501	20011026 <--
WO 2002060434	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248221	A1	20020812	AU 2002-248221	20011026 <--
EP 1347755	A2	20031001	EP 2001-997102	20011026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517938	T	20040617	JP 2002-560626	20011026

PRIORITY APPLN. INFO.:		US 2000-244698P	P 20001031
		WO 2001-US49501	W 20011026

OTHER SOURCE(S): MARPAT 137:140435
GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator

activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their preparation is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alkaline hydrolysis (100%), to give title compound II. PPAR binding assays using human recombinant PPAR are described without data. Co-administration of compds. I with a variety of other drug categories, including a number of specific drugs, is claimed.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of benzopyrancarboxylic acid
derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 43 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:504607 CAPLUS
DOCUMENT NUMBER: 137:93594
TITLE: Preparation of cyclobutene derivatives as agents for use in combination with HMG-CoA reductase inhibitors
INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori; Kurata, Hitoshi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 674 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051396	A1	20020704	WO 2001-JP11294	20011221 <--
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002216402	A1	20020708	AU 2002-216402	20011221 <--
JP 2002255799	A	20020911	JP 2001-391028	20011225 <--
PRIORITY APPLN. INFO.:			JP 2000-395948 A	20001226
			WO 2001-JP11294 W	20011221

OTHER SOURCE(S): MARPAT 137:93594
GI



I

AB The title compds. I [R1 is cycloalkyl, aryl, etc.; R2 is cycloalkyl, aryl, heterocyclic ring, etc.; R3 and R4 are each hydrogen or the like; A is a group of the general formula Q1 (wherein R5 is hydrogen or the like; R6 is an amine residue or the like; X and Y are each oxygen or the like; and Z is a single bond or the like); G is alkylene or the like; and when the dotted line is a double bond, D is carbon atom and E is :NO, when the dotted line is a single bond, D is CH or the like and E is NH or the like] are prepared A pharmaceutical composition containing HMG-CoA reductase inhibitor and I is claimed. In hamsters fed feed containing 0.3% cholesterol and 10% coconut oil, the administration of pravastatin at 0.01% (weight/weight) alone caused 26% increase in high d. lipoprotein cholesterol; the combined administration of pravastatin and a cyclobutene derivative of this invention at 0.01% (weight/weight) caused 41% increase in high d. lipoprotein cholesterol. A formulation containing pravastatin sodium and a compound of this invention is given.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of composition containing cyclobutene derivative and HMG-CoA reductase inhibitor)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 44 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:762797 CAPLUS
DOCUMENT NUMBER: 135:308909
TITLE: Pharmaceutical combinations containing AT1-receptor antagonist
INVENTOR(S): De Gasparo, Marc; Graves, Kurt C.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001076573	A2	20011018	WO 2001-EP4115		20010410 <--
WO 2001076573	A3	20030417			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2405793	A1	20011018	CA 2001-2405793		20010410 <--
EP 1326604	A2	20030716	EP 2001-931583		20010410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001009966	A	20030805	BR 2001-9966		20010410
JP 2003530342	T	20031014	JP 2001-574091		20010410
HU 2004000475	A2	20040628	HU 2004-475		20010410
HU 2004000475	A3	20060228			
CN 1651087	A	20050810	CN 2004-10101218		20010410
RU 2298418	C2	20070510	RU 2002-129558		20010410
NO 2002004921	A	20021107	NO 2002-4921		20021011 <--
MX 2002PA10090	A	20030212	MX 2002-PA10090		20021011
ZA 2002008203	A	20031107	ZA 2002-8203		20021011
US 20040023840	A1	20040205	US 2003-257559		20030103
AU 2005209657	A1	20050929	AU 2005-209657		20050909
US 20070105894	A1	20070510	US 2006-590215		20061031
PRIORITY APPLN. INFO.:			US 2000-196743P	P	20000412
			AU 2001-58323	A3	20010410
			WO 2001-EP4115	W	20010410

US 2003-257559 B1 20030103

AB The invention relates to a combination of at least 2 therapeutic combination components selected from the group consisting of an AT1-receptor antagonist or an AT1 receptor antagonist combined with a diuretic or, in each case, a salt, a HMG-CoA reductase inhibitor or a salt and an ACE inhibitor or a salt for the prevention of, delay of progression of, treatment of selected diseases and conditions. Thus, tablets were prepared by granulation of the mixture of valsartan 80.00, Avicel PH-102 54.00
Crospovidone 20.00, Aerosil-200 0.75, and Mg stearate 2.5 mg/unit, and blending this composition with a mixture of Aerosil-200 0.75, Mg stearate 2.00,
and Diolack pale red 00F34899 7.00 mg/unit.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combinations containing AT1-receptor antagonist)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 45 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:597795 CAPLUS
DOCUMENT NUMBER: 135:185456
TITLE: Tumor necrosis factor (TNF-α) inhibitors
INVENTOR(S): Sugiyama, Yasuo; Odaka, Hiroyuki; Naruo, Ken-ichi; Funatsu, Masami; Ikeya, Kazuaki; Suzuki, Yoshiharu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058443	A1	20010816	WO 2001-JP881	20010208 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2399396		A1	20010816	CA 2001-2399396		20010208 <--
AU 2001032245		A5	20010820	AU 2001-32245		20010208 <--
EP 1275388		A1	20030115	EP 2001-904345		20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2001294526		A	20011023	JP 2001-33761		20010209 <--
US 20030018040		A1	20030123	US 2002-203292		20020808
PRIORITY APPLN. INFO.:				JP 2000-38266	A	20000210
				WO 2001-JP881	W	20010208

AB TNF-inhibitors containing at least one compound selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pravastatin, itavastatin and (+)-(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid and salts thereof which have sufficiently favorable properties as drugs, for example, exhibiting excellent preventive and therapeutic effects on TNF-α-associated diseases such as inflammatory diseases without showing any side effects.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as tumor necrosis factor inhibitor as pharmaceutical)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 46 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2003:20841 CAPLUS
DOCUMENT NUMBER:	139:190335
TITLE:	Management of dyslipidemia in the high-risk patient
AUTHOR(S):	Stein, Evan A.
CORPORATE SOURCE:	Metabolic and Atherosclerosis Research Center and Medical Research Laboratories International, Cincinnati, OH, USA
SOURCE:	American Heart Journal (2002), 144(6, Suppl.), S43-S50 CODEN: AHJOA2; ISSN: 0002-8703
PUBLISHER:	Mosby, Inc.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review. Lipid-lowering agents have been shown to reduce morbidity and mortality associated with coronary heart disease (CHD), particularly in high-risk patients. The identification and treatment of these patients should therefore be a high priority for clinicians. Guidelines from medical organizations, such as the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) and the American Diabetes Association (ADA),

suggest that patients with low-d. lipoprotein cholesterol (LDL-C) levels ≥130 mg/dL, and perhaps even those with levels ≥100 mg/dL, should receive drug therapy. Optimal LDL-C levels have been set at <100 mg/dL and <115 mg/dL for high-risk patients by US and European guidelines, resp. However, a recent survey shows that only about 20% of high-risk patients currently meet these goals. In order to achieve therapeutic targets for LDL-C, the statins are the foundation of treatment, as they are the most effective and best-tolerated form of lipid-lowering therapy. Other therapeutic options include bile acid sequestrants, niacin, and plant stanols, although seldom as monotherapy. Combination therapy with a statin and one of these other lipid-lowering agents can be useful in patients who are unable to achieve target lipid levels through monotherapy. There remains, however, a need for addnl. agents. Some of the new options for reducing LDL-C levels that may be available in the near future include 2 new statins, pitavastatin and rosuvastatin. In patients with heterozygous familial hypercholesterolemia, rosuvastatin, which is currently under review by the Food and Drug Administration (FDA), has been shown to produce significantly greater redns. in LDL-C than atorvastatin over its full dose range. In comparative clin. trials, it has also enabled more patients with primary hypercholesterolemia to meet lipid goals than atorvastatin, simvastatin, and pravastatin. Inhibitors of bile acid transport or cholesterol absorption may also have therapeutic value. The first cholesterol absorption inhibitor, ezetimibe, which has just been approved by the FDA, appears to be most effective when combined with a statin. It is anticipated that such new options will allow clinicians to optimize the management of dyslipidemia in high-risk patients, thereby reducing the morbidity and mortality of CHD.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(management of dyslipidemia in high-risk patient)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 47 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:943329 CAPLUS

DOCUMENT NUMBER: 139:94494

TITLE: Mechanism of HMG-CoA reductase inhibitors

AUTHOR(S): Morikawa, Shigeru; Hamakubo, Takao; Kodama, Tatsuhiko

CORPORATE SOURCE: Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, 153-8904, Japan

SOURCE: Naibunpi, Tonyobyoka (2002), 15(2), 168-176
CODEN: NATOFF; ISSN: 1341-3724
PUBLISHER: Kagaku Hyoronsha
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review. Mechanism of HMG-CoA reductase inhibitors is reviewed including cholesterol synthesis, the inhibitory effects of statin (pitavastatin) on HMG-CoA reductase at cholesterol synthesis as well as the structure and pathway of sterol regulatory element binding protein (SREBP)and its regulatory mechanism.
IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mechanism of HMG-CoA reductase inhibitors)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 48 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:927184 CAPLUS
DOCUMENT NUMBER: 138:14048
TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523 <--
WO 2002096357	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030092697	A1	20030515	US 2002-153342		20020522
US 7105556	B2	20060912			
CA 2449006	A1	20021205	CA 2002-2449006		20020523 <--
AU 2002310141	A1	20021209	AU 2002-310141		20020523 <--
EP 1401433	A2	20040331	EP 2002-737192		20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005506954	T	20050310	JP 2002-592870		20020523
HU 2006000226	A2	20061128	HU 2006-226		20020523
US 20060189598	A1	20060824	US 2006-406799		20060419
PRIORITY APPLN. INFO.:			US 2001-294505P	P	20010530
			US 2002-153342	A3	20020522
			WO 2002-US16628	W	20020523

OTHER SOURCE(S): MARPAT 138:14048

GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that ≥1 of x2 and x3 ≠ 0; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that ≥1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepared as antidiabetic and antiobesity agents (no data). Thus, the title compound (II) was prepared in 6 steps.

IT 147511-69-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related
compds. as antidiabetic and antiobesity agents)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 49 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:777650 CAPLUS
DOCUMENT NUMBER: 137:299910
TITLE: Therapeutic combinations containing COX-2 inhibitors for cardiovascular and inflammatory diseases treatment
INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.; Krul, Elaine S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078626	A2	20021010	WO 2002-US9346	20020328 <--
WO 2002078626	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442328	A1	20021010	CA 2002-2442328	20020328 <--
AU 2002255929	A1	20021015	AU 2002-255929	20020328 <--
US 20030199482	A1	20031023	US 2002-107809	20020328
EP 1435956	A2	20040714	EP 2002-725362	20020328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1527709	A	20040908	CN 2002-810210	20020328
JP 2005507854	T	20050324	JP 2002-576894	20020328
MX 2003PA08835	A	20041206	MX 2003-PA8835	20030929
US 20040186154	A1	20040923	US 2004-473045	20040506

PRIORITY APPLN. INFO.:			
US 2001-279239P	P	20010328	
WO 2002-US9346	W	20020328	

AB The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT inhibitor combined with COX-2 inhibitor. A further therapeutic combination

comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor. Thus, a tablet composition contained benzothiepine 5, celecoxib 20, lactose 54, microcryst. cellulose 15, HPMC 3, Croscarmellose sodium 2, and Mg stearate 1 mg/tablet.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations containing COX-2 inhibitors for cardiovascular and inflammatory diseases treatment)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 50 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:744783 CAPLUS
DOCUMENT NUMBER: 138:297319
TITLE: The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC
AUTHOR(S): Morikawa, Shigeru; Takabe, Wakako; Mataki, Chikage; Kanke, Toru; Itoh, Takahiro; Wada, Youichiro; Izumi, Akashi; Saito, Yasushi; Hamakubo, Takao; Kodama, Tatsuhiko
CORPORATE SOURCE: Departments of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
SOURCE: Journal of Atherosclerosis and Thrombosis (2002), 9(4), 178-183
CODEN: JATHEH; ISSN: 1340-3478
PUBLISHER: Japan Atherosclerosis Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Large-scale clin. trials have demonstrated significant redns. in cardiovascular events following statin therapy. The observed benefit of statin therapy, however, may be greater in these trials than is to be expected from lowering lipid levels alone. In order to clarify the mechanism by which statins prevent cardiovascular events in vascular wall cells, we investigated the changes in gene expression profiles after incubation with atorvastatin or pitavastatin in cultured human umbilical vein endothelial cells using DNA microarrays. Statins affected the expression levels of genes involved in inflammation, coagulation, and vascular constriction. The mRNA levels for interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) decreased after statin treatment. Statins reduced mRNA levels of plasminogen activator inhibitor-1 (PAI-1) and increased the mRNA levels of thrombomodulin. Statins reduced the mRNA levels of endothelin-1 and increased the mRNA

levels of nitric oxide synthase-3 (eNOS). These results show that, statins are clin. effective because of their ability to change the gene expression profile of endothelial cells thereby preventing vascular events.

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); BIOL (Biological study)
(effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 51 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:637483 CAPLUS
DOCUMENT NUMBER: 137:185311
TITLE: Preparation of 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
INVENTOR(S): Adams, Alan D.; Jones, A. Brian; Berger, Joel P.; Dropinski, James F.; Elbrecht, Alexander; Liu, Kun; Macnaul, Karen Lamb; Shi, Guo-qiang; Von, Langen Derek J.; Zhou, Gaochao
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064094	A2	20020822	WO 2002-US4680	20020205 <--
WO 2002064094	A3	20030612		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2437118	A1	20020822	CA 2002-2437118	20020205 <--

AU 2002251978	A1	20020828	AU 2002-251978		20020205 <--
AU 2002251978	B2	20070719			
EP 1366012	A2	20031203	EP 2002-721022		20020205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004521124	T	20040715	JP 2002-563891		20020205
US 20040092596	A1	20040513	US 2003-470954		20030730
US 7091230	B2	20060815			
US 20060122242	A1	20060608	US 2006-334152		20060118
PRIORITY APPLN. INFO.:			US 2001-267809P	P	20010209
			WO 2002-US4680	W	20020205
			US 2003-470954	A3	20030730

OTHER SOURCE(S): MARPAT 137:185311

GI



I



II

AB Title compds. I [R1 = halo, alkyl, alkoxy; R2 = alkyl, alicyclic; R3 = alkyl, aryl, alicyclic, heterocycle, etc.; R4 = H, OH, alkoxy, aryloxy, halo or R3-4 may be joined together to yield 5- or 6-membered heterocycle; R5 = H, halo; R6 = H, halo, CH3, CF3; Ar1 = Ph, thienyl, thiazolyl, oxazolyl, pyridyl; X = O, S; Z = COOH, tetrazole, carboxamide] were prepared For instance, 2,4-dipropylresorcinol was converted to 2,4-dihydroxy-3,5-dipropyl-α,α,α-trifluoroacetophenone (CH2Cl2, TFAA, AlCl3) and subsequently treated with i. hydroxylamine•HCl, MeOH, reflux; ii. Ac2O; iii. pyridine, reflux which afforded 5,7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole. The benzisoxazole was reacted with Me 2-bromo-2-phenylacetate (DMF, Cs2CO3) and the product saponified to give II. I are potent agonists of the peroxisome proliferator activated receptor and are useful in the treatment of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR-α and/or PPAR-γ mediated diseases.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 2-aryloxy-2-arylalkanoic acids
for diabetes and lipid disorders)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 52 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:594636 CAPLUS
DOCUMENT NUMBER: 137:135097
TITLE: Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
INVENTOR(S): Jones, A. Brian; Acton, John J., III
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060388	A2	20020808	WO 2002-US3119	20020125 <--
WO 2002060388	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434491	A1	20020808	CA 2002-2434491	20020125 <--
AU 2002240235	A1	20020812	AU 2002-240235	20020125 <--
EP 1357908	A2	20031105	EP 2002-706128	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521119	T	20040715	JP 2002-560584	20020125
US 20040073037	A1	20040415	US 2003-470483	20030729
US 6852738	B2	20050208		

PRIORITY APPLN. INFO.: US 2001-264955P P 20010130
WO 2002-US3119 W 20020125

OTHER SOURCE(S): MARPAT 137:135097

AB A class of acyl sulfamides comprises compds. that are potent ligands for PPARγ receptors and generally have antagonist or partial agonist activity. The compds. may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPARγ receptor-mediated diseases, disorders and conditions, alone or in combination with one or more other compds. Other compds. are selected from insulin sensitizers, insulin or insulin mimetics, sulfonylureas, α-glucosidase inhibitors, cholesterol lowering agents, PPARδ agonists, antiobesity compds., an ileal bile

acid transporter inhibitor, and agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cyclooxygenase-2 selective inhibitors.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acyl sulfamides and other drugs for treatment of metabolic disorders mediated by PPARγ receptors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 53 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:574926 CAPLUS
DOCUMENT NUMBER: 137:135094
TITLE: The use of substituted azetidinone compounds for the treatment of sitosterolemia
INVENTOR(S): Davis, Harry R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058696	A2	20020801	WO 2002-US1195	20020125 <--
WO 2002058696	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434430	A1	20020801	CA 2002-2434430	20020125 <--
AU 2002243557	A1	20020806	AU 2002-243557	20020125 <--
AU 2002243557	B2	20060105		
EP 1355644	A2	20031029	EP 2002-709050	20020125
EP 1355644	B1	20060628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006641	A	20040225	BR 2002-6641	20020125
HU 2003003929	A2	20040301	HU 2003-3929	20020125

CN 1527707	A	20040908	CN 2002-804102		20020125
JP 2004532186	T	20041021	JP 2002-559030		20020125
NZ 526532	A	20050128	NZ 2002-526532		20020125
AT 331512	T	20060715	AT 2002-709050		20020125
ES 2266459	T3	20070301	ES 2002-709050		20020125
RU 2317078	C2	20080220	RU 2003-126187		20020125
ZA 2003005691	A	20041223	ZA 2003-5691		20030723
IN 2003CN01144	A	20050422	IN 2003-CN1144		20030724
NO 2003003359	A	20030925	NO 2003-3359		20030725
MX 2003PA06729	A	20031024	MX 2003-PA6729		20030725
HK 1055679	A1	20070427	HK 2003-107963		20031104
AU 2005246926	A1	20060119	AU 2005-246926		20051219
JP 2007091763	A	20070412	JP 2007-5232		20070112
KR 2007120617	A	20071224	KR 2007-727662		20071127
PRIORITY APPLN. INFO.:			US 2001-264645P	P	20010126
			AU 2002-243557	A3	20020125
			JP 2002-559030	A3	20020125
			WO 2002-US1195	W	20020125
			KR 2003-709673	A3	20030722

OTHER SOURCE(S): MARPAT 137:135094
GI



AB The invention discloses the use of sterol absorption-inhibiting compds., pharmaceutical compns. thereof, therapeutic combinations, and their use in combination with other lipid-lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided. The methodol. and compns. of the invention use substituted azetidinone compds., e.g. I (preparation described).

IT 147511-69-1, Itavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(azetidinone derivs. for treatment of sitosterolemia)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 54 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:540258 CAPLUS
DOCUMENT NUMBER: 137:109267
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20020094977	A1	20020718	US 2001-7407		20011204 <--
US 6627636	B2	20030930			
US 20020013334	A1	20020131	US 2001-875155		20010606 <--
PRIORITY APPLN. INFO.:			US 2000-211595P	P	20000615
			US 2001-875155	A2	20010606

OTHER SOURCE(S): MARPAT 137:109267
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis (no data). A multistep synthesis of II is reported.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-

dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 55 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:487576 CAPLUS
DOCUMENT NUMBER: 137:41758
TITLE: Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents and in the treatment of atherosclerosis
INVENTOR(S): Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050090	A1	20020627	WO 2001-US49127	20011217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432798	A1	20020627	CA 2001-2432798	20011217 <--
CA 2432798	C	20070227		
AU 2002031049	A	20020701	AU 2002-31049	20011217 <--
EP 1347987	A1	20031001	EP 2001-991315	20011217
EP 1347987	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002269	A2	20031028	HU 2003-2269	20011217
BR 2001016212	A	20031230	BR 2001-16212	20011217
JP 2004516299	T	20040603	JP 2002-551983	20011217
AT 279425	T	20041015	AT 2001-991315	20011217
NZ 525722	A	20041126	NZ 2001-525722	20011217
PT 1347987	T	20050131	PT 2001-991315	20011217
ES 2230385	T3	20050501	ES 2001-991315	20011217
EP 1593670	A1	20051109	EP 2005-4699	20011217

EP 1593670		B1	20070808			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
RU 2297422		C2	20070420	RU 2003-122520		20011217
AT 369334		T	20070815	AT 2005-4699		20011217
ES 2287826		T3	20071216	ES 2005-4699		20011217
ZA 2003003694		A	20040813	ZA 2003-3694		20030513
IN 2003CN00940		A	20050422	IN 2003-CN940		20030613
NO 2003002806		A	20030819	NO 2003-2806		20030619
MX 2003PA05671		A	20031006	MX 2003-PA5671		20030620
HK 1056735		A1	20050506	HK 2003-109136		20031215
EP 1510521		A1	20050302	EP 2004-19610		20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
HK 1084945		A1	20080104	HK 2006-104984		20050714
AU 2007201970		A1	20070524	AU 2007-201970		20070503
PRIORITY APPLN. INFO.:				US 2000-256875P	P	20001220
				EP 2001-991315	A3	20011217
				WO 2001-US49127	W	20011217
				EP 2004-19610	A3	20040818
				HK 2005-106006	A3	20050714
				AU 2006-202618	A3	20060620

OTHER SOURCE(S): MARPAT 137:41758

AB Hypocholesterolemic sugar-substituted 2-azetidinone compds. are disclosed, as are a method of lowering cholesterol by administering these compds., pharmaceutical compns. containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

IT 147511-69-1, Itavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 56 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:465809 CAPLUS
DOCUMENT NUMBER:	137:37669
TITLE:	Antilipemic agents containing lignan analogs and HMG-CoA reductase inhibitors
INVENTOR(S):	Mizui, Takuji; Hara, Seijiro

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047678	A1	20020620	WO 2001-JP10660	20011206 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430760	A1	20020620	CA 2001-2430760	20011206 <--
AU 2002018529	A	20020624	AU 2002-18529	20011206 <--
EP 1358879	A1	20031105	EP 2001-270213	20011206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016082	A	20031223	BR 2001-16082	20011206
TW 231210	B	20050421	TW 2001-90130334	20011207
MX 2003PA05251	A	20030925	MX 2003-PA5251	20030612
US 20040048805	A1	20040311	US 2003-450138	20030612

PRIORITY APPLN. INFO.:		
JP 2000-379347	A	20001213
WO 2001-JO10660	W	20011206
WO 2001-JP10660	W	20011206

AB Disclosed are antilipemic agents characterized by containing Me 1-(3,4-dimethoxyphenyl)-3-(ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate or its glucuronic acid conjugate and an HMG-CoA reductase inhibitor, such as pravastatin and lovastatin.

IT 147511-69-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Itavastatin; antilipemic agents containing lignan analogs and HMG-CoA reductase inhibitors)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 57 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:392237 CAPLUS
DOCUMENT NUMBER: 136:401651
TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20020061901	A1	20020523	US 2001-8154		20011204	<--
US 6620821	B2	20030916				
US 20020028826	A1	20020307	US 2001-875218		20010606	<--
US 20040024216	A1	20040205	US 2003-602753		20030624	
PRIORITY APPLN. INFO.:			US 2000-211594P	P	20000615	
			US 2001-875218	A2	20010606	
			US 2001-8154	A3	20011204	

OTHER SOURCE(S): MARPAT 136:401651
GI



I



II

AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Prepns. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner

similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 58 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:314754 CAPLUS

DOCUMENT NUMBER: 136:335247

TITLE: Compositions for treatment of conditions associated with elevated Lp(a) levels using a thyromimetic compound combined with a statin

INVENTOR(S): Steele, Ronald Edward; Dardik, Beatriz N.

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032408	A2	20020425	WO 2001-EP12075	20011018 <--
WO 2002032408	A3	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023626	A5	20020429	AU 2002-23626	20011018 <--

PRIORITY APPLN. INFO.:			
US 2000-242036P	P	20001020	
WO 2001-EP12075	W	20011018	

OTHER SOURCE(S): MARPAT 136:335247

AB Disclosed are methods for the treatment of conditions associated with elevated levels of Lp(a), such as coronary heart disease (CHD), ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, reduction in necrosis after myocardial infarction, dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a pharmaceutical combination of a thyromimetic compound and a statin.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of conditions associated with elevated Lp(a) levels
using thyromimetic compound combined with statin)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 59 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:157564 CAPLUS
DOCUMENT NUMBER: 136:205424
TITLE: Combinations of insulin secretion enhancer, HMG-CoA reductase inhibitors and acetylcholinesterase inhibitors
INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015892	A2	20020228	WO 2001-EP9586	20010820 <--
WO 2002015892	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002014952	A5	20020304	AU 2002-14952		20010820 <--
EP 1359907	A2	20031112	EP 2001-983442		20010820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004519424	T	20040702	JP 2002-520813		20010820
US 20040087630	A1	20040506	US 2003-362341		20030618
PRIORITY APPLN. INFO.:			US 2000-643642	A	20000822
			WO 2001-EP9586	W	20010820

AB The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) HMG-Co-A reductase inhibitors or a pharmaceutically acceptable salt thereof; and (ii) ACE inhibitors or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier. Formulations were given as examples, e.g., tablets containing nateglinide.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of insulin secretion enhancer, HMG-CoA reductase inhibitors and acetylcholinesterase inhibitors)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 60 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:90008 CAPLUS
DOCUMENT NUMBER: 136:151071
TITLE: Preparation of N-substituted indoles for treating diabetes
INVENTOR(S): Acton, John J., III; Black, Regina Marie; Jones, Anthony Brian; Wood, Harold Blair
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008188	A1	20020131	WO 2001-US22979	20010720 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2415742	A1	20020131	CA 2001-2415742	20010720	<--
EP 1305285	A1	20030502	EP 2001-954836	20010720	
EP 1305285	B1	20070516			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004513076	T	20040430	JP 2002-514095	20010720	
AT 362468	T	20070615	AT 2001-954836	20010720	
US 20020042441	A1	20020411	US 2001-912961	20010725	<--
US 6525083	B2	20030225			
PRIORITY APPLN. INFO.:			US 2000-220778P	P 20000725	
			WO 2001-US22979	W 20010720	

OTHER SOURCE(S): MARPAT 136:151071

GI



I



II

AB The title indoles having aryloxyacetic acid substituents [I; R1 = Me, optionally substituted with 1-3 F atoms; R2-R4 = H, halo, alkyl, etc.; R5, R6 = H, F, OH, alkyl; and R5 and R6 groups that are on the same carbon atom optionally may be joined to form a cyclopropyl group; R7, R8 = H, F, alkyl; or CR7R8 may form cycloalkyl; R9 = H, alkyl; Ar1 = (un)substituted Ph, naphthyl, pyridyl, quinolyl; X = CO, SO2, CH2, CHMe, CMe2, CF2, cyclopropylidene; Y = O, S; n = 0-5] which are agonists or partial agonists of PPAR gamma, and are useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR mediated diseases, disorders and conditions, were prepared E.g., a multi-step synthesis of (2S)-II was given.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-substituted indoles for treating diabetes)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 61 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:747642 CAPLUS
DOCUMENT NUMBER: 135:293982
TITLE: Pharmaceuticals containing a β-blocker and a cholesterol-lowering agent
INVENTOR(S): Bondjers, Goeran; Wiklund, Olov; Wikstrand, John
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074394	A1	20011011	WO 2001-SE663	20010327 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2403160	A1	20011011	CA 2001-2403160	20010327 <--
EP 1272219	A1	20030108	EP 2001-916044	20010327
EP 1272219	B1	20061213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009753	A	20030204	BR 2001-9753	20010327
HU 2003000332	A2	20030628	HU 2003-332	20010327
HU 2003000332	A3	20050329		
JP 2003528928	T	20030930	JP 2001-572136	20010327
EE 200200570	A	20040415	EE 2002-570	20010327
NZ 521351	A	20040827	NZ 2001-521351	20010327
AT 347909	T	20070115	AT 2001-916044	20010327
ES 2276774	T3	20070701	ES 2001-916044	20010327
US 20030060477	A1	20030327	US 2002-220790	20020904

ZA 2002007107	A	20031204	ZA 2002-7107		20020904	
IN 2002MN01245	A	20050304	IN 2002-MN1245		20020912	
NO 2002004732	A	20021002	NO 2002-4732		20021002	<--
MX 2002PA09705	A	20040226	MX 2002-PA9705		20021002	
HK 1051325	A1	20070525	HK 2003-103659		20030523	
US 20040192784	A1	20040930	US 2004-824170		20040414	
PRIORITY APPLN. INFO.:			SE 2000-1188	A	20000403	
			SE 2000-2352	A	20000622	
			WO 2001-SE663	W	20010327	
			US 2002-220790	B1	20020904	

AB The present invention relates to pharmaceutical formulations comprising a β-blocker and a cholesterol-lowering agent in admixt. with an adjuvant, a diluent or carrier, as well as a kit of parts, a method for treatment and use of the formulations for the prophylactic or therapeutic treatment of atherosclerosis, hypercholesterolemia and hyperlipoproteinemia. Thus, a 3-yr placebo-controlled pilot study was designed to investigate the effect of metoprolol succinate controlled-release formulation on atherosclerosis in patients with primary hypercholesterolemia on concomitant therapy with a cholesterol-lowering agent. Total cholesterol, HDL cholesterol and heart rate decreased more in the metoprolol controlled-release group compared with the placebo group.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing β-blocker and cholesterol-lowering agent)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 62 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2001:635873 CAPLUS
DOCUMENT NUMBER:	135:200468
TITLE:	Method for producing pharmaceutical dosage forms containing statins and D-mannitol
INVENTOR(S):	Laich, Tobias; Poertner, Carola; Henck, Jan-Olav
PATENT ASSIGNEE(S):	Bayer Aktiengesellschaft, Germany
SOURCE:	PCT Int. Appl., 23 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001062230	A1	20010830	WO 2001-EP1565	20010213 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10008506	A1	20010913	DE 2000-10008506	20000224 <--
EP 1259227	A1	20021127	EP 2001-907526	20010213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030031720	A1	20030213	US 2002-204837	20020823
PRIORITY APPLN. INFO.:			DE 2000-10008506 A	20000224
			WO 2001-EP1565 W	20010213

AB The invention relates to a method for producing a granulate while using spray-dried D-mannitol and to the production of pharmaceutical dosage forms comprised of granulates of this type. The invention addnl. relates to granulates obtained by using this method and to pharmaceutical dosage forms, which contain statins, especially cerivastatin, and which can be produced from the granulates. Thus 0.4 mg cerivastatin tablets were produced. For granulation the following ingredients were used (g): D-mannitol 5228.3; cerivastatin-sodium (from cerivastatin-lactone) 25.00; sodium hydroxide 8.12; polyvinylpyrrolidone 112.50; water 437.50. Cerivastatin-lactone was dissolved in 233.91 g water with 2.12 g sodium hydroxide; the rest of sodium hydroxide and water were used to dissolve PVP; the two solns. were combined. D-Mannitol was placed into a mixer and the solution was added; the load was discharged via a 4 mm diameter cutter. Granules were dried in fluidized bed; mixed with crosslinked PVP and magnesium stearate and pressed into 90 mg tablets.

IT 147511-69-1, Itavastatin
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(method for producing pharmaceutical dosage forms containing statins and D-mannitol)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 63 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:359020 CAPLUS
DOCUMENT NUMBER: 146:330827
TITLE: Bile preparations for colorectal disorders
INVENTOR(S): Yoo, Seo Hong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 996,945.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070072828	A1	20070329	US 2006-522162	20060915
US 6251428	B1	20010626	US 1999-357549	19990720 <--
US 20020031558	A1	20020314	US 2001-778154	20010205 <--
US 7303768	B2	20071204		
US 20050158408	A1	20050721	US 2004-996945	20041124
AU 2004325203	A1	20060601	AU 2004-325203	20041124
CA 2588168	A1	20060601	CA 2004-2588168	20041124
EP 1819318	A1	20070822	EP 2004-812094	20041124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101065110	A	20071031	CN 2004-80044467	20041124
BR 2004019213	A	20071218	BR 2004-19213	20041124
AU 2006203315	A1	20060824	AU 2006-203315	20060803
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
KR 2007098821	A	20071005	KR 2007-714361	20070622

PRIORITY APPLN. INFO.:		
US 1998-94069P	P	19980724
US 1999-357549	A2	19990720
US 2000-180268P	P	20000204
US 2001-778154	A2	20010205
US 2004-996945	A2	20041124
AU 2001-36685	A3	20010205
WO 2004-US39507	A	20041124

AB The present disclosure relates to methods and compns. to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compns. may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of ppts. or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bile prepns. for colorectal disorders)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 64 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:971711 CAPLUS
DOCUMENT NUMBER: 140:23243
TITLE: Orally administered peptides for treatment of atherosclerosis and osteoporosis and with the ability to synergize statin activity
INVENTOR(S): Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Pat. Appl. 2003 171,277.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030229015	A1	20031211	US 2002-273386	20021016
US 7166578	B2	20070123		
US 6664230	B1	20031216	US 2000-645454	20000824
US 20030045460	A1	20030306	US 2001-896841	20010629
US 6933279	B2	20050823		
WO 2002015923	A1	20020228	WO 2001-US26497	20010823 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1375299	A	20021023	CN 2001-103876	20010823 <--
CN 1739787	A	20060301	CN 2005-10103876	20010823
CN 1911439	A	20070214	CN 2006-10100670	20010823
CN 1931358	A	20070321	CN 2006-10100667	20010823
CN 1931359	A	20070321	CN 2006-10100669	20010823
CN 1943781	A	20070411	CN 2006-10100668	20010823
EP 1864675	A1	20071212	EP 2007-7775	20010823
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20030171277	A1	20030911	US 2002-187215	20020628
US 7144862	B2	20061205		
US 20040266671	A1	20041230	US 2003-423830	20030425
US 7199102	B2	20070403		
US 20040254120	A1	20041216	US 2003-649378	20030826
US 7148197	B2	20061212		

CA 2501943		A1	20040429	CA 2003-2501943	20031014
WO 2004034977		A2	20040429	WO 2003-US32442	20031014
WO 2004034977		A3	20041125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003284129		A1	20040504	AU 2003-284129	20031014
EP 1562624		A2	20050817	EP 2003-776360	20031014
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1744909		A	20060308	CN 2003-80106367	20031014
JP 2006508179		T	20060309	JP 2005-501402	20031014
IN 2005CN00613		A	20060428	IN 2005-CN613	20050412
JP 2006056899		A	20060302	JP 2005-304531	20051019
US 20070032430		A1	20070208	US 2006-407390	20060418
US 20080045459		A1	20080221	US 2006-431412	20060509
US 20070060527		A1	20070315	US 2006-485620	20060711
JP 2006312650		A	20061116	JP 2006-220831	20060814
US 20070254839		A1	20071101	US 2007-689037	20070321
JP 2007277250		A	20071025	JP 2007-118451	20070427
AU 2007237157		A1	20071213	AU 2007-237157	20071126

PRIORITY APPLN. INFO.:	US 2000-645454	A2	20000824
	US 2001-896841	A2	20010629
	WO 2001-US26497	A2	20010823
	US 2002-187215	A2	20020628
	CN 2001-103876	A3	20010823
	CN 2001-817280	A3	20010823
	CN 2005-10103876	A3	20010823
	EP 2001-966198	A3	20010823
	JP 2002-520844	A3	20010823
	US 2002-273386	A2	20021016
	US 2003-423830	A2	20030425
	US 2003-494449P	P	20030811
	US 2003-649378	A3	20030826
	WO 2003-US32442	W	20031014
	US 2005-676431P	P	20050429
	US 2005-697495P	P	20050707
	JP 2005-304531	A3	20051019
	AU 2006-200035	A3	20060106
	JP 2006-220831	A3	20060814

AB This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high d. lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally administered peptides for treatment of atherosclerosis and osteoporosis and with the ability to synergize statin activity)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 259 THERE ARE 259 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 65 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:888713 CAPLUS
DOCUMENT NUMBER: 137:384764
TITLE: Process for producing (3R,5S)-7-substituted-3,5-dihydroxyhept-6-enoic acid
INVENTOR(S): Nishino, Shigeyoshi; Yokoyama, Shuji; Kawachi, Yasuhiro; Sasaki, Hiroshi
PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092570	A1	20021121	WO 2002-JP4710	20020515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005047803	A	20050224	JP 2001-145358	20010515
AU 2002308984	A1	20021125	AU 2002-308984	20020515 <--

PRIORITY APPLN. INFO.:		
JP 2001-145358	A	20010515
WO 2002-JP4710	W	20020515

OTHER SOURCE(S): MARPAT 137:384764
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a process for producing a (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid represented by the formula (I) which comprises optically resolving with an achiral amine compound a mixture of optical isomers of a 7-[2-cyclopropyl-4-(4-

fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid represented by the formula (II). The optical resolution involves contacting II with an achiral amine to form II achiral amine salt, recrystg. the salt to form I achiral amine salt, and contacting the I achiral recrystn. amine salt with an acid to give I. This process does not use expensive chiral amines and is suitable for industrial preparation of I which is an intermediate for an anticholesteremic agent (HMG-CoA reductase inhibitor). Thus, 4.21 g II (preparation given), 1.07 g benzylamine, and 30 mL EtOAc were added to a 50 mL flask and cooled to 0° with stirring, upon which crystals precipitated The precipitated crystals were filtered, washed with EtOAc cooled at 0°, and dried under reduced pressure to give 94.9% II benzylamine salt. II benzylamine salt (4.22 g) and 84 mL THF were added to a 100 mL flask, warmed to 50° with stirring to give a homogeneous solution, and cooled to 0°, upon which crystals precipitated The precipitated crystals were filtered and washed with 42 mL THF cooled at 0°. This procedure was repeated twice to give 2.52 g I benzyl amine salt (60.0%) which (2.11 g) and 10 mL MeOH were added to a 50 mL flask, adjusted to pH 3.5 by adding 1 M aqueous HCl, and extracted with 10 mL EtOAc twice, followed by drying the EtOAc extract over anhydrous MgSO4 and concentration to give 1.66 g I (99.0%).

IT 147511-69-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid by optical resolution using achiral amine via formation of achiral amine salt, recrystn., and treatment with acid)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 66 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:777648 CAPLUS
DOCUMENT NUMBER: 137:257659
TITLE: Therapeutic combinations for cardiovascular and inflammatory indications
INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078625	A2	20021010	WO 2002-US9185	20020327 <--
WO 2002078625	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002306868	A1	20021015	AU 2002-306868	20020327 <--
US 20030199482	A1	20031023	US 2002-107809	20020328
CN 1527709	A	20040908	CN 2002-810210	20020328
PRIORITY APPLN. INFO.:			US 2001-279239P P	20010328
			WO 2002-US9185 W	20020327

AB The invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an Apical Sodium codependent Bile acid Transport (ASBT) inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor.

IT 147511-69-1, Itavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG CoA reductase, cyclooxygenase and sodium codependent bile acid transport inhibitors for cardiovascular and inflammatory diseases in humans)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 67 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:396703 CAPLUS
DOCUMENT NUMBER: 135:10035
TITLE: HMG-CoA reductase inhibitors for ameliorating abnormal bone states
INVENTOR(S): Bagi, Cedo M.

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037876	A2	20010531	WO 2000-EP11466	20001117 <--
WO 2001037876	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-167267P P 19991124

AB This application relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of abnormal conditions ameliorated by concurrent decrease in bone resorption and stimulation of bone formation. This invention also relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of conditions ameliorated by a decrease in plasma calcium levels. Thus, tablets contained cerivastatin 25, microcryst. cellulose 200, colloidal SiO2 10, and stearic acid 5 mg/tablet.

IT 147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitors for ameliorating abnormal bone states)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 68 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1088938 CAPLUS
DOCUMENT NUMBER: 147:398709
TITLE: Methods and compositions for controlling body weight and appetite
INVENTOR(S): Lippa, Arnold S.; Epstein, Joseph W.; Basile, Anthony; Tizzano, Joseph T.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27pp., Cont.-in-part of U.S. Ser. No. 442,743.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070225351	A1	20070927	US 2006-603974	20061121
WO 2002066427	A2	20020829	WO 2002-US845	20020111 <--
WO 2002066427	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040132797	A1	20040708	US 2004-466457	20040210
US 7098229	B2	20060829		

PRIORITY APPLN. INFO.:		
WO 2002-US845	W	20020111
US 2004-466457	A1	20040210
US 2006-442743	A2	20060530
US 2001-758883	A	20010111

AB The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The invention also provides novel compns. and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dyslipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compns. of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for controlling body weight and appetite)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 69 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:2160 CAPLUS
DOCUMENT NUMBER: 142:86655
TITLE: Orally administered peptides synergism with statins and therapeutical application in the treatment of atherosclerosis and osteoporosis
INVENTOR(S): Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 273,386.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040266671	A1	20041230	US 2003-423830	20030425
US 7199102	B2	20070403		
US 6664230	B1	20031216	US 2000-645454	20000824
US 20030045460	A1	20030306	US 2001-896841	20010629
US 6933279	B2	20050823		
CN 1375299	A	20021023	CN 2001-103876	20010823 <--
CN 1739787	A	20060301	CN 2005-10103876	20010823
CN 1911439	A	20070214	CN 2006-10100670	20010823
CN 1931358	A	20070321	CN 2006-10100667	20010823
CN 1931359	A	20070321	CN 2006-10100669	20010823
CN 1943781	A	20070411	CN 2006-10100668	20010823
EP 1864675	A1	20071212	EP 2007-7775	20010823
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20030171277	A1	20030911	US 2002-187215	20020628
US 7144862	B2	20061205		
US 20030229015	A1	20031211	US 2002-273386	20021016
US 7166578	B2	20070123		
US 20040254120	A1	20041216	US 2003-649378	20030826
US 7148197	B2	20061212		
CA 2501943	A1	20040429	CA 2003-2501943	20031014
WO 2004034977	A2	20040429	WO 2003-US32442	20031014
WO 2004034977	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003284129	A1	20040504	AU 2003-284129		20031014
EP 1562624	A2	20050817	EP 2003-776360		20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1744909	A	20060308	CN 2003-80106367		20031014
JP 2006508179	T	20060309	JP 2005-501402		20031014
IN 2005CN00613	A	20060428	IN 2005-CN613		20050412
JP 2006056899	A	20060302	JP 2005-304531		20051019
US 20070032430	A1	20070208	US 2006-407390		20060418
US 20080045459	A1	20080221	US 2006-431412		20060509
US 20070060527	A1	20070315	US 2006-485620		20060711
JP 2006312650	A	20061116	JP 2006-220831		20060814
US 20070254839	A1	20071101	US 2007-689037		20070321
JP 2007277250	A	20071025	JP 2007-118451		20070427
AU 2007237157	A1	20071213	AU 2007-237157		20071126
PRIORITY APPLN. INFO.:			US 2000-645454	A2	20000824
			US 2001-896841	A2	20010629
			US 2002-187215	A2	20020628
			US 2002-273386	A2	20021016
			CN 2001-103876	A3	20010823
			CN 2001-817280	A3	20010823
			CN 2005-10103876	A3	20010823
			EP 2001-966198	A3	20010823
			JP 2002-520844	A3	20010823
			WO 2001-US26497	A2	20010823
			US 2003-423830	A2	20030425
			US 2003-494449P	P	20030811
			US 2003-649378	A3	20030826
			WO 2003-US32442	W	20031014
			US 2005-676431P	P	20050429
			US 2005-697495P	P	20050707
			JP 2005-304531	A3	20051019
			AU 2006-200035	A3	20060106
			JP 2006-220831	A3	20060814

AB This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high d. lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally administered peptides synergism with statins and therapeutical application in treatment of atherosclerosis and osteoporosis)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 285 THERE ARE 285 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 70 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1082022 CAPLUS
DOCUMENT NUMBER: 142:49262
TITLE: Orally administered small peptides synergize statin activity, and therapeutic uses
INVENTOR(S): Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: U.S. Pat. Appl. Publ., 159 pp., Cont.-in-part of U.S. Ser. No. 423,830.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040254120	A1	20041216	US 2003-649378	20030826
US 7148197	B2	20061212		
US 6664230	B1	20031216	US 2000-645454	20000824
US 20030045460	A1	20030306	US 2001-896841	20010629
US 6933279	B2	20050823		
CN 1375299	A	20021023	CN 2001-103876	20010823 <--
CN 1739787	A	20060301	CN 2005-10103876	20010823
CN 1911439	A	20070214	CN 2006-10100670	20010823
CN 1931358	A	20070321	CN 2006-10100667	20010823
CN 1931359	A	20070321	CN 2006-10100669	20010823
CN 1943781	A	20070411	CN 2006-10100668	20010823
EP 1864675	A1	20071212	EP 2007-7775	20010823
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20030171277	A1	20030911	US 2002-187215	20020628
US 7144862	B2	20061205		
US 20030229015	A1	20031211	US 2002-273386	20021016
US 7166578	B2	20070123		
US 20040266671	A1	20041230	US 2003-423830	20030425
US 7199102	B2	20070403		
US 20050164950	A1	20050728	US 2004-913800	20040806
AU 2004264944	A1	20050224	AU 2004-264944	20040810
CA 2534676	A1	20050224	CA 2004-2534676	20040810
WO 2005016280	A2	20050224	WO 2004-US26288	20040810
WO 2005016280	A3	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1660112	A2	20060531	EP 2004-786504	20040810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1867348	A	20061122	CN 2004-80029870	20040810
JP 2007512228	T	20070517	JP 2006-523396	20040810
HU 2007000157	A2	20070529	HU 2007-157	20040810
JP 2006056899	A	20060302	JP 2005-304531	20051019
MX 2006PA01743	A	20060512	MX 2006-PA1743	20060213
NO 2006001139	A	20060508	NO 2006-1139	20060309
IN 2006KN00576	A	20070803	IN 2006-KN576	20060310
US 20070060527	A1	20070315	US 2006-485620	20060711
JP 2006312650	A	20061116	JP 2006-220831	20060814
JP 2007277250	A	20071025	JP 2007-118451	20070427
AU 2007237157	A1	20071213	AU 2007-237157	20071126

PRIORITY APPLN. INFO.:

US 2000-645454	A2	20000824
US 2001-896841	A2	20010629
US 2002-187215	A2	20020628
US 2002-273386	A2	20021016
US 2003-423830	A2	20030425
US 2003-494449P	P	20030811
CN 2001-103876	A3	20010823
CN 2001-817280	A3	20010823
CN 2005-10103876	A3	20010823
EP 2001-966198	A3	20010823
JP 2002-520844	A3	20010823
WO 2001-US26497	A2	20010823
US 2003-649378	A1	20030826
WO 2004-US26288	W	20040810
JP 2005-304531	A3	20051019
AU 2006-200035	A3	20060106
JP 2006-220831	A3	20060814

OTHER SOURCE(S): MARPAT 142:49262

AB The invention provides peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-β high d. lipoprotein-like particles and/or to promote lipid transport and detoxification. The invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more antiinflammatory at any given dose.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally administered small peptides synergize statin activity, and therapeutic uses)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 301 THERE ARE 301 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 71 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:392331 CAPLUS
DOCUMENT NUMBER: 140:406798
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040092573	A1	20040513	US 2003-602752		20030624
US 6812345	B2	20041102			
US 20020013334	A1	20020131	US 2001-875155		20010606 <--
PRIORITY APPLN. INFO.:			US 2000-211595P	P	20000615
			US 2001-875155	B2	20010606

OTHER SOURCE(S): MARPAT 140:406798
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other

disorders)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 72 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:354734 CAPLUS
DOCUMENT NUMBER: 140:368701
TITLE: Orally administered peptides to synergize statin activity, and their use in the treatment of atherosclerosis and osteoporosis
INVENTOR(S): Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004034977	A2	20040429	WO 2003-US32442	20031014
WO 2004034977	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1375299	A	20021023	CN 2001-103876	20010823 <--
US 20030229015	A1	20031211	US 2002-273386	20021016
US 7166578	B2	20070123		
US 20040266671	A1	20041230	US 2003-423830	20030425
US 7199102	B2	20070403		
CA 2501943	A1	20040429	CA 2003-2501943	20031014
AU 2003284129	A1	20040504	AU 2003-284129	20031014
EP 1562624	A2	20050817	EP 2003-776360	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006508179	T	20060309	JP 2005-501402		20031014
AU 2007237157	A1	20071213	AU 2007-237157		20071126
PRIORITY APPLN. INFO.:			US 2002-273386	A	20021016
			US 2003-423830	A	20030425
			US 2000-645454	A2	20000824
			US 2001-896841	A2	20010629
			WO 2001-US26497	A2	20010823
			US 2002-187215	A2	20020628
			WO 2003-US32442	W	20031014
			AU 2006-200035	A3	20060106

AB The invention provides peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high-d. lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the station to be used at significantly lower dosages and/or cause the statins to be significantly more antiinflammatory at any given dose.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides to synergize statin activity, and use in treatment of atherosclerosis and osteoporosis)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 73 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:59557 CAPLUS
DOCUMENT NUMBER:	140:105270
TITLE:	Methods for treatment of multiple sclerosis with statins
INVENTOR(S):	Mach, Francois
PATENT ASSIGNEE(S):	Novlmmune S.A., Switz.
SOURCE:	U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 56,608. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20040013643	A1	20040122	US 2003-349549	20030122
US 20020156122	A1	20021024	US 2001-960471	20010919 <--
US 20020159974	A1	20021031	US 2002-56608	20020123 <--
CA 2474077	A1	20030731	CA 2003-2474077	20030122
CA 2474201	A1	20030731	CA 2003-2474201	20030122
WO 2003061702	A1	20030731	WO 2003-IB607	20030122
WO 2003061702	A9	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003061703	A1	20030731	WO 2003-IB646	20030122
WO 2003061703	A9	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1467763	A1	20041020	EP 2003-701708	20030122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
EP 1467764	A1	20041020	EP 2003-702899	20030122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2003202797	B2	20071129	AU 2003-202797	20030122
US 20070003636	A1	20070104	US 2006-432861	20060512
PRIORITY APPLN. INFO.:			US 2000-664871	A2 20000919
			US 2001-960471	A2 20010919
			US 2002-56608	A2 20020123
			WO 2003-IB607	W 20030122
			WO 2003-IB646	W 20030122
			US 2005-233584	B1 20050922
			US 2005-502113	B1 20060512

AB New uses of statins as novel types of immunomodulator are claimed. More specifically, the invention relates to methods for treating multiple sclerosis through the administration of one or more statins, and even more advantageously, in combination with other multiple sclerosis agents or treatments, such as β-interferons or copaxone. Clin. studies on treatment of multiple sclerosis patients with combinations of statins (atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, rosuvastatin, velostatin, cerivastatin, itavastatin) and other drugs (Avonex, copaxone, Rebif, Betaseron) are reported. In vitro studies on statin effects on MHC class II expression, CD40 expression, and lymphocyte activation are described.

IT 147511-69-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of multiple sclerosis with statins)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 74 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:435299 CAPLUS
DOCUMENT NUMBER: 139:22062
TITLE: Preparation of substituted 2-azetidinones and use as hypocholesterolemic agents
INVENTOR(S): Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 23,295.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030105028	A1	20030605	US 2002-166942	20020611
US 6982251	B2	20060103		
US 20020137690	A1	20020926	US 2001-23295	20011217 <--
EP 1593670	A1	20051109	EP 2005-4699	20011217
EP 1593670	B1	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030119757	A1	20030626	US 2002-247032	20020919
US 20030119796	A1	20030626	US 2002-247085	20020919
US 7056906	B2	20060606		
US 20030119428	A1	20030626	US 2002-247397	20020919
US 7053080	B2	20060530		
US 20040214811	A1	20041028	US 2002-247099	20020919
US 7071181	B2	20060704		
EP 1510521	A1	20050302	EP 2004-19610	20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HK 1084945	A1	20080104	HK 2006-104984	20050714
US 20060009399	A1	20060112	US 2005-216515	20050831
AU 2007201970	A1	20070524	AU 2007-201970	20070503

PRIORITY APPLN. INFO.:

US 2000-256875P	P	20001220
US 2001-23295	A2	20011217
US 2001-264396P	P	20010126
US 2001-323839P	P	20010921
US 2001-323840P	P	20010921
US 2001-323841P	P	20010921
US 2001-323937P	P	20010921
US 2001-324118P	P	20010921
EP 2001-991315	A3	20011217

US 2002-57323	A2	20020125
US 2002-166942	A2	20020611
US 2002-247397	A3	20020919
EP 2004-19610	A3	20040818
HK 2005-106006	A3	20050714
AU 2006-202618	A3	20060620

OTHER SOURCE(S): MARPAT 139:22062
GI





AB The authors report the preparation of substituted 2-azetidinone compds. I [R1 = H, SO3H, Q1, etc., R3, R4, R5 = H, C1-C6 alkyl, CO-aryl, etc., R6 = H, C1-C6 alkyl, COMe, etc., R8 = H, alkyl, R26 = H, OH, F, etc., Ar1 = aryl, heteroaryl, etc., Ar2 = aryl, heteroaryl, etc., L = covalent bond, CO, phenylene, etc., Q = (CH2)n, n = 2-6, spiro group, etc.], as well as methods of lowering cholesterol by administering said compds., pharmaceutical compns. containing them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis. Thus, 14C-Sch 58235 was converted to the benzylic glucuronide II using UDPGA (uridine diphosphoglucuronosyltransferase) as catalyst.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents combined with a cholesterol biosynthesis inhibitor for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 75 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:889587 CAPLUS
DOCUMENT NUMBER: 137:370080
TITLE: Preparation of benzisoxazolyloxyacetic acids for treatment of diabetes and lipid disorders
INVENTOR(S): Liu, Kun; Xu, Libo; Jones, A. Brian
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 782,856, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020173663	A1	20021121	US 2001-932834	20010817 <--
US 6569879	B2	20030527		

PRIORITY APPLN. INFO.: US 2000-183593P P 20000218
US 2001-782856 B2 20010214
OTHER SOURCE(S): MARPAT 137:370080
GI



I

AB Title compds. [I; R1, R2 = H, F, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl; R1R2C = cycloalkyl; R3, R4 = alkyl, alkenyl, alkynyl, Cl; X = N, CR; Y = O, S, NR; Z = O, S; R = H, (substituted) alkyl, alkenyl, alkynyl; R5 = H, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkenyloxy, alkynyloxy, aryl, cycloalkyl, heteroaryl, etc.; with provisos], were prepared as PPARα and/or PPARγ agonists and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus, hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity,

vascular restenosis, inflammation, etc. (no data). Thus, 5,7-dipropyl-6-OH-3-CF3-1,2-benzisoxazole (preparation given) was stirred with Me α-bromoisobutyrate and Cs2CO3 in DMF for 7 days at 60° to give Me 2-[(5,7-dipropyl-3-CF3-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionate.

IT 147511-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of benzisoxazolyloxyacetic acids for treatment of diabetes and lipid disorders)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 76 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1342404 CAPLUS
DOCUMENT NUMBER: 146:55531
TITLE: Use of substituted azetidinone compounds for the treatment of sitosterolemia and other conditions
INVENTOR(S): Davis, Harry R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 49pp., Cont.-in-part of U.S. Ser. No. 57,629.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060287254	A1	20061221	US 2006-437454	20060519
US 20020169134	A1	20021114	US 2002-57629	20020125 <--
US 20050080071	A1	20050414	US 2004-890847	20040714
AU 2005246926	A1	20060119	AU 2005-246926	20051219
JP 2007091763	A	20070412	JP 2007-5232	20070112
WO 2007136696	A2	20071129	WO 2007-US11825	20070517

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2001-264645P	P	20010126
US 2002-57629	A2	20020125
AU 2002-243557	A3	20020125
JP 2002-559030	A3	20020125
US 2006-437454	A	20060519

OTHER SOURCE(S): MARPAT 146:55531

AB The invention discloses pharmaceutical compns. comprising a azetidinone derivative sterol absorption inhibitor, a cholesterol ester-exchange protein (CETP) inhibitor, and/or HMG-CoA reductase inhibitor, as well as methods for treating sitosterolemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, mixed dyslipidemia, vascular events prevention, and related disorders in a mammal in need thereof by administering the pharmaceutical compns. to the mammal. Compound preparation is described.

IT 147511-69-1, Itavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing substituted azetidinone compds. as sterol
absorption inhibitors plus cholesterol ester-exchange protein inhibitor and/or HMG-CoA reductase inhibitor for treatment of sitosterolemia and other conditions)

RN 147511-69-1 CAPLUS

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L10 ANSWER 77 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:616068 CAPLUS
DOCUMENT NUMBER: 134:125381
TITLE: Synthetic optically pure statins
AUTHOR(S): Farnier, Michel; Picard, Sylvie
CORPORATE SOURCE: Point Medical, Rond Point de la Nation, Dijon, 21000, Fr.
SOURCE: IDrugs (2000), 3(8), 897-906
CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER: Current Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 95 refs. covering the chemical structure and mechanism of action of statins, i.e. atorvastatin, cerivastatin, rosuvastatin, and itavastatin in their lipid-lowering effects and their role in the prevention of atherosclerosis and coronary artery disease.

IT 147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mechanism of action of optically pure statins)
RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 78 OF 78 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:452012 CAPLUS
DOCUMENT NUMBER: 133:171608
TITLE: Itavastatin Nissan Chemical Industries
AUTHOR(S): Flores, Nicholas A.
CORPORATE SOURCE: Academic Cardiology Unit National Heart and Lung Institute, Imperial College School of Medicine, London, W2 1NY, UK
SOURCE: Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs (2000), 2(3), 279-283
CODEN: CCPRFX; ISSN: 1464-8482
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 32 refs. Itavastatin is an HMG-CoA reductase inhibitor being developed jointly by Nissan and Kowa Kogyo for the potential treatment of atherosclerosis and hyperlipidemia. In Dec. 1999, the companies confirmed that they had submitted an NDA for itavastatin for the potential treatment of hypercholesterolemia. A double-blind trial of 266 patients with hypercholesterolemia showed that itavastatin lowered total blood cholesterol in all doses and also decreased low d. lipoprotein (LDL) cholesterol. The results indicate that the once-daily dose required for the drug is significantly lower to that required for atorvastatin (Lipitor; Parke-Davis). Itavastatin is a liver-selective drug with longer-acting HMG-CoA reductase inhibitor and higher cholesterol lowering potency than pravastatin (Sankyo) or simvastatin. The cholesterol-lowering effect is probably attributable to the enhancement of hepatic LDL receptor. Itavastatin is active in several animal species including rats, guinea-pigs and dogs. In May 1999, Kowa and Nissan Chemical Industries reached an agreement to grant co-marketing rights in Japan to Sankyo.
IT 147511-69-1, Itavastatin
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(itavastatin for treatment of atherosclerosis and hyperlipidemia in humans)

RN 147511-69-1 CAPLUS
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



=>